Antibodies that bind to ox40 and their uses

ABSTRACT

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 13/545,708, filed Jul. 10, 2012, now U.S. Pat. No. 8,748,585, whichclaims the benefit of U.S. Provisional Application No. 61/506,491, filedJul. 11, 2011, each of which is incorporated by reference herein intheir entirety.

REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB

The content of the electronically submitted sequence listing (Name:3305_(—)0020002_SEQLISTING.ascii.txt; Size: 113,020 bytes; and Date ofCreation: Mar. 20, 2014) is herein incorporated by reference in itsentirety.

FIELD OF THE INVENTION

The present invention relates to antagonist antibodies or fragmentsthereof that bind to human OX40. More specifically, the presentinvention relates to an antagonist antibody or fragment thereof thatbinds to human OX40 comprising a heavy chain CDR1 comprising the aminoacid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising theamino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising alight chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4,and/or a light chain CDR2 comprising the amino acid sequence of SEQ IDNO: 5 and/or a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 6.

BACKGROUND OF THE INVENTION

OX40 is a member of the TNFR-superfamily of receptors and was firstidentified in 1987 as a 50 kDa glycoprotein expressed on activated CD4+T cells from the rat (Paterson D J et al., (1987) Mol. Immunol. 24:1281-90). The extracellular ligand binding domain of OX40 is composed of3 full cysteine-rich domains (CRDs) and a partial, fourth C-terminal CRD(Bodmer J L et al., (2002) Trends Biochem. Sci. 27: 19-26). The ligandfor OX40 is OX40L (CD252) and 3 copies of OX40 bind to the trimericligand to form the OX40-OX40L complex (Compaan D M & Hymowitz S G (2006)Structure, 14: 1321-1330). OX40 is a membrane-bound receptor; however asoluble isoform has also been detected (Taylor L & Schwarz H (2001) J.Immunol. Methods, 255: 67-72). Unlike CD28, OX40 is not constitutivelyexpressed on naïve T cells but is induced after engagement of the T-CellReceptor (TCR). OX40 is a secondary costimulatory molecule, expressedafter 24 to 72 hours following activation; its ligand, OX40L, is alsonot expressed on resting antigen presenting cells, but is followingtheir activation. OX40 is expressed mainly by activated CD4+ T cells andto a limited extent, by activated CD8+ T cells (Salek-Ardakani S et al.,(2006) Curr. Immunol. Rev. 2: 37-53).

SUMMARY OF THE INVENTION

The present disclosure relates generally to antagonist antibodies orfragments thereof that bind to human OX40, methods for their preparationand use, including methods for treating OX40 mediated disorders. Theantagonist antibodies or fragments thereof of the present invention thatbind to human OX40 are antagonistic antibodies and do not show agonisticeffects and/or activate human OX40 on binding.

In one aspect, the present disclosure provides an antagonist antibody orfragment thereof that binds to human OX40 comprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chainCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavychain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/orcomprising a light chain CDR1 comprising the amino acid sequence of SEQID NO: 4, and/or a light chain CDR2 comprising the amino acid sequenceof SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acidsequence of SEQ ID NO: 6.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising a heavychain variable region sequence comprising the amino acid sequence of SEQID NO: 7. In a further aspect the present invention provides anantagonist antibody or fragment thereof that binds to human OX40comprising a heavy chain variable framework region that is the productof or derived from a human gene selected from the group consisting of:IGHV2-70*10 (SEQ ID NO: 19), IGHV2-70*01 (SEQ ID NO: 20), IGHV2-70*13(SEQ ID NO: 21), IGHV2-5*09 (SEQ ID NO: 22), and IGHV2-70*11 (SEQ ID NO:23).

In a further aspect the present invention provides an antagonistantibody or fragment thereof comprising a heavy chain sequencecomprising the amino acid sequence of SEQ ID NO: 32 and wherein theheavy chain variable framework region comprises at least one amino acidmodification from the corresponding heavy chain variable frameworkregion of the corresponding murine antibody.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising a lightchain variable region sequence comprising the amino acid sequence of SEQID NO: 8. In a further aspect the present invention provides anantagonist antibody or fragment thereof that binds to human OX40comprising a light chain variable framework region that is the productof or derived from a human gene selected from the group consisting of:IGKV3-11*01 (SEQ ID NO: 24), IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01(SEQ ID NO: 26), IGKV3-11*02 (SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO:28).

In a further aspect the present invention provides an antagonistantibody or fragment thereof comprising a light chain variable frameworkregion that is the product of or derived from human gene IGKV3-11*01(SEQ ID NO: 24) and wherein the light chain variable framework regioncomprises at least one amino acid modification from the correspondingframework region of the light chain variable region of the correspondingmurine antibody.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising a heavychain sequence selected from the group consisting of SEQ ID NOS: 32, 33,34, 35, 36, 37 and 38. In a further aspect the present inventionprovides an antagonistic antibody or fragment thereof that binds tohuman OX40 comprising a light chain sequence selected from the groupconsisting of SEQ ID NOS: 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 and 49.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising:

(a) a heavy chain sequence comprising the amino acid sequence of SEQ IDNO: 37 or 38; and(b) a light chain sequence comprising the amino acid sequence of SEQ IDNO: 47.

In a further aspect the present invention provides an antagonisticantibody or fragment thereof that binds to human OX40 comprising a heavychain variable region comprising the amino acid sequence selected fromthe group consisting of SEQ ID NOS: 58, 59, 79 and 80. In a furtheraspect the present invention provides an antagonistic antibody orfragment thereof that binds to human OX40 comprising a light chainvariable region comprising the amino acid sequence selected from thegroup consisting of SEQ ID NOS: 60, 86, 87 and 89.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising:

-   (a) a heavy chain variable region comprising the amino acid sequence    of SEQ ID NO: 58 or 59; and-   (b) a light chain variable region comprising the amino acid sequence    of SEQ ID NO: 60.

In a further aspect the present invention provides an antagonisticantibody or fragment thereof that binds to human OX40, wherein theantibody comprises a human IgG4 Fc region, wherein the antibody has noFc-mediated cytotoxicity activity. In a further aspect the presentinvention provides an antagonistic antibody or fragment thereof thatbinds to human OX40, wherein the antibody comprises a human IGHG1 Fcregion, wherein the antibody is competent for cytotoxicity mechanismssuch as antibody dependent cellular cytotoxicity (ADCC). In a preferredaspect, the antagonistic antibody or fragment thereof that binds tohuman OX40 has a non fucosylated IGHG1 Fc region and exhibits enhancedFc-mediated cytotoxicity mechanisms such as ADCC.

In another aspect, the disclosure of the present invention alsodescribes antagonistic humanized antibodies or fragments thereof thatbind with a similar affinity to human OX40 as the corresponding chimericantibody e.g. retain at least 75% of the OX40 binding affinity (K_(D))of the corresponding chimeric antibody or have at least equivalent orhigher OX40 binding affinity (K_(D)) when compared to the correspondingchimeric antibody. In a further aspect the present invention provides anantagonist antibody or fragment thereof that binds to an epitope withinthe second domain of human OX40 extracellular region.

The disclosure of the present invention also provides isolated nucleicacids encoding antibodies and fragments thereof that bind to human OX40,vectors and host cells comprising the nucleic acid or the vector.Compositions comprising the antagonist antibody or fragment thereof anda pharmaceutically acceptable carrier and immunoconjugates comprisingthe antagonist antibody or fragment thereof linked to a therapeuticagent are also provided.

The present disclosure also provides methods for treating OX40 mediateddisorders. In one aspect, in an in vitro model of alloreactive T cellactivation and proliferation (mixed lymphocyte reaction; MLR), anantagonistic antibody or fragment thereof efficiently inhibits MLR intwo different individuals (responders), with an EC₅₀ value ofapproximately 100 ng/mL. Furthermore, in a xenogenic graft versus hostreaction, a model for allogenic graft versus host disease (GVHD)observed after bone marrow transplant in human patients, an antagonisticantibody or fragment thereof potently suppressed the GVHD reaction.

The present disclosure also provides kits and articles of manufacturecomprising the antibody or fragments thereof, a composition or animmunoconjugate for the treatment of an OX40 mediated disorder.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A and FIG. 1B: (A) Direct-binding ELISA on immobilized recombinanthuman OX40-his. Binding of chimeric 2F8 and 1D4 antibodies on human OX40was measured by direct ELISA. Various concentrations (ranging from 10 to0.01 mg/ml) of 1D4 (black histograms) and 2F8 (white histograms) wereincubated with 2 mg/ml of recombinant human OX40-his tagged proteincoated overnight at 4° C. in a 96-well plate. Binding of each antibodyto OX40 was detected by horseradish peroxidise (HRP)-conjugated antihuman antibody. (B) Competitive ELISA on immobilized recombinant humanOX40-Fc. Inhibitory effects of chimeric 1D4 and 2F8 on OX40/OX40Linteraction were evaluated by blocking ELISA. Various concentrations(ranging from 10 to 0.01 mg/ml) of 1D4 (black histograms) and 2F8 (whitehistograms) were incubated with 2 mg/ml of recombinant human OX40-Fctagged protein coated overnight at 4° C. in a 96-well plate. After fiveminutes, a fixed concentration of biotinylated recombinant human OX40L(0.04 mg/ml) was added to each well and incubated for 30 minutes at roomtemperature. Binding of OX40L to OX40 was detected usingStreptavidin-HRP.

FIG. 2: One way mixed lymphocyte reaction (MLR) measured by ³H thymidineincorporation. Bars show the mean ³H-thymidine incorporation (counts) ofat least triplicates ±standard error of the mean. Isotype control(trastuzumab) and positive control (efalizumab) are shown. Effectorstands for only effector cells. Effector+target represent a measurementwhere antibodies have been omitted.

FIG. 3A and FIG. 3B: Flow cytometry analysis of chimeric 1D4 antibody

(A) Staining on human activated peripheral blood mononuclear cells(PBMCs) and HPB-ALL cells. Histogram plots show the fluorescenceintensity (X-axis) and relative cell number (% of max events−Y-Axis).The type of cells stained is indicated. Human PBMC were activated withPHA and IL-2 for 48 h prior measurements.(B) Staining on activated cynomologus monkey PBMCs. Binding of thechimeric 1D4 antibody to cynomologus OX40 was evaluated by flowcytometry. Peripheral blood mononuclear cells (PBMCs) were isolated fromwhole blood collected from a cynomologus monkey and 3×10⁶ cells werecultured for 50 hours in the presence of 10 mg/ml of PHA and 100 U/ml ofrhuIL-2. Activated PBMCs were incubated with 25 mg/ml of either controlantibody (upper profile (i)) or biotinylated sheep anti-human OX40antibody (middle profile (ii)) or biotinylated chimeric 1D4 antibody(lower profile (iii)). Binding of each antibody to cynomologus OX40 wasdetected with streptavidin-APC.

FIGS. 4A, B, C, D, E and F: Surface Plasmon resonance measurements ofanti-OX40 antibodies. Data are expressed as number of response(abbreviated RU; Y axis) vs. time (X axis).

FIG. 4A—VH1/VL1 antibody vs 1D4 chimera.

FIG. 4B—VH1, VH2, and VH3 based humanized antibodies (as indicated) vs1D4 chimera.

FIG. 4C—examples of poor binders: VH4/VL4, VH5/VL4, VH5/VL5, andVH5/VL6.

FIG. 4D—examples of weak binders (VH5/VL9 and VH4/VL9) and good binders(VH6/VL9 and VH7/VL9).

FIG. 4E—VH7 based humanized antibodies.

FIG. 4F—VH6/VL9 has best binding properties over 1D4 chimera andhumanized variant VH7/VL9.

FIG. 5A and FIG. 5B: Sequence Alignment. Alignment of the heavy chain(FIG. 5A) or light chain (FIG. 5B) variable region of 1D4 with selectedgermline frameworks (IGHV 2-70*10 (SEQ ID NO: 19) and IGKV3-11*01 (SEQID NO: 24)) from IMGT and back-mutated variable region variants (VH1(SEQ ID NO: 29), VH2 (SEQ ID NO: 77), VH3 (SEQ ID NO: 78), VH4 (SEQ IDNO: 79), VH5 (SEQ ID NO: 80), VH6 (SEQ ID NO: 58), VH7 (SEQ ID NO: 59),(VL1 (SEQ ID NO: 30), VL2 (SEQ ID NO: 81), VL3 (SEQ ID NO: 82), VL4 (SEQID NO: 83), VL5 (SEQ ID NO: 84), VL6 (SEQ ID NO: 85), VL7 (SEQ ID NO:86), VL8 (SEQ ID NO: 87), VL9 (SEQ ID NO: 60) VL10 (SEQ ID NO: 88), VL11(SEQ ID NO: 89).

FIG. 6: Thermostability measurements of humanized anti-OX40anti-antibody VH6/VL9 FAB fragment using differential scanningcalorimetry. Data are expressed as excess molar heat capacity(abbreviated Cp [kcal/mol/° C.]; Y axis) vs. temperature (X axis).

FIG. 7: Epitope Characterisation. This figure shows humanized anti-OX40anti-antibody VH6/VL9 epitope based on ELISA assay results as describedin Example 7.

FIG. 8A and FIG. 8B: Mixed lymphocyte reaction (MLR) measured by ³Hthymidine incorporation. FIGS. 8A and 8B show the results of mixedlymphocyte reaction from two unrelated donors. The proliferation wasmeasured by ³H-thymidine incorporation. The graphs show the absolutecounts values for each condition ±SEM. Responder cells were untreatedPBMCs, stimulator cells were mitomycin-treated PBMCs. All conditionswith test antibodies were done with responder cells mixed withheterologous stimulator PBMCs. The positive control was Efalizumab (antiLFA-1 antibody).

FIG. 9: Xenogeneic graft versus host reaction model. This figure showsthe percent survival within groups of eight animals for each mentionedcondition. Vehicle: only PBS. The vertical dotted line indicates thelast day of treatment. No mortality and no symptoms were observed in agroup of two irradiated control animals that did not received PBMCs (notshown).

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure relates to antagonist antibodies and fragmentsthereof that bind to human OX40.

The term “human OX40” as used herein includes variants, isoforms, andspecies homologs of human OX40. Accordingly, antibodies of thisdisclosure may, in certain cases, cross-react with OX40 from speciesother than human. In certain embodiments, the antibodies may becompletely specific for one or more human OX40 proteins and may notexhibit species or other types of non-human cross-reactivity. Thecomplete amino acid sequence of an exemplary human OX40 has Swiss-Protaccession number P43489 (TNR4_HUMAN; SEQ ID NO: 12). OX40 is also knownas CD134, TNFRSF4, ACT35 or TXGP1 L. Human OX40 is designated GeneID:7293 by Entrez Gene, and HGNC: 11918 by HGNC. OX40 has also beendesignated CD134 (cluster of differentiation 134). OX40 can be encodedby the gene designated TNFRSF4/OX40.

The use of “human OX40” herein encompasses all known or as yetundiscovered alleles and polymorphic forms of human OX40. The terms“human OX40”, “OX40” or “OX40 Receptor” are used herein equivalently andmean “human OX40” if not otherwise specifically indicated.

The term “OX40 ligand” or “OX40L” are used herein equivalently andinclude OX40 ligand, specifically human OX40 ligand. OX40L is a memberof the TNF superfamily and is also known as gp34 or CD252. OX40L hasalso been designated CD252 (cluster of differentiation 252) and has thesequence database accession number P23510 (Swiss-Prot) or Q6FGS4(Uniprot). OX40L is expressed on the surface of activated B cells, Tcells, dendritic cells and endothelial cells.

The term “antibody or fragment thereof that binds to human OX40” as usedherein includes antibodies or a fragment thereof that binds to humanOX40 e.g. human OX40 in isolated form, with an affinity (K_(D)) of 500nM or less, preferably 200 nM or less, more preferably 150 nM or less,more preferably 120 nM or less, even more preferably 110 nM or less. Theterm “antibody or fragment thereof that binds to human OX40” includesantibodies or antigenic binding fragments thereof.

The terms “antagonistic antibody” or “antagonist antibody” are usedherein equivalently and include an antibody that is capable ofinhibiting and/or neutralising the biological signalling activity ofOX40, for example by blocking binding or substantially reducing bindingof OX40 to OX40 ligand and thus inhibiting or reducing the signalisationpathway triggered by OX40 and/or inhibiting or reducing an OX40-mediatedcell response like lymphocyte proliferation, cytokine expression, orlymphocyte survival.

The term “antibody” as referred to herein includes whole antibodies andany antigen binding fragments or single chains thereof. An “antibody”refers to a glycoprotein comprising at least two heavy (H) chains andtwo light (L) chains inter-connected by disulfide bonds, or an antigenbinding fragment thereof. Each heavy chain is comprised of a heavy chainvariable region (abbreviated herein as VH) and a heavy chain constantregion. The heavy chain constant region is comprised of three domains,CH1, CH2 and CH3. Each light chain is comprised of a light chainvariable region (abbreviated herein as VL) and a light chain constantregion. The light chain constant region is comprised of one domain, CL.The VH and VL regions can be further subdivided into regions ofhypervariability, termed complementarity determining regions (CDR) withare hypervariable in sequence and/or involved in antigen recognitionand/or usually form structurally defined loops, interspersed withregions that are more conserved, termed framework regions (FR or FW).Each VH and VL is composed of three CDRs and four FWs, arranged fromamino-terminus to carboxy-terminus in the following order: FW1, CDR1,FW2, CDR2, FW3, CDR3, FW4. The amino acid sequences of FW1, FW2, FW3,and FW4 all together constitute the “non-CDR region” or “non-extendedCDR region” of VH or VL as referred to herein.

The term “heavy chain variable framework region” as referred herein maycomprise one or more (e.g., one, two, three and/or four) heavy chainframework region sequences (e.g., framework 1 (FW1), framework 2 (FW2),framework 3 (FW3) and/or framework 4 (FW4)).

Preferably the heavy chain variable region framework comprises FW1, FW2and/or FW3, more preferably FW1, FW2 and FW3. The term “light chainvariable framework region” as referred herein may comprise one or more(e.g., one, two, three and/or four) light chain framework regionsequences (e.g., framework 1 (FW1), framework 2 (FW2), framework 3 (FW3)and/or framework 4 (FW4)). Preferably the light chain variable regionframework comprises FW1, FW2 and/or FW3, more preferably FW1, FW2 andFW3.

The variable regions of the heavy and light chains contain a bindingdomain that interacts with an antigen. The constant regions of theantibodies may mediate the binding of the immunoglobulin to host tissuesor factors, including various cells of the immune system (e.g., effectorcells) and the First component (Clq) of the classical complement system.

Antibodies are grouped into classes, also referred to as isotypes, asdetermined genetically by the constant region. Human constant lightchains are classified as kappa (CK) and lambda (Cλ) light chains. Heavychains are classified as mu (μ), delta (δ), gamma (γ), alpha (α), orepsilon (ε), and define the antibody's isotype as IgM, IgD, IgG, IgA,and IgE, respectively. Thus, “isotype” as used herein is meant any ofthe classes and/or subclasses of immunoglobulins defined by the chemicaland antigenic characteristics of their constant regions. The known humanimmunoglobulin isotypes are IgG1 (IGHG1), IgG2 (IGHG2), IgG3 (IGHG3),IgG4 (IGHG4), IgA1 (IGHA1), IgA2 (IGHA2), IgM (IGHM), IgD (IGHD), andIgE (IGHE). The so-called human immunoglobulin pseudo-gamma IGHGP generepresents an additional human immunoglobulin heavy constant region genewhich has been sequenced but does not encode a protein due to an alteredswitch region (Bensmana M et al., (1988) Nucleic Acids Res. 16(7):3108). In spite of having an altered switch region, the humanimmunoglobulin pseudo-gamma IGHGP gene has open reading frames for allheavy constant domains (CH1-CH3) and hinge. All open reading frames forits heavy constant domains encode protein domains which align well withall human immunoglobulin constant domains with the predicted structuralfeatures. This additional pseudo-gamma isotype is referred herein asIgGP or IGHGP. Other pseudo immunoglobulin genes have been reported suchas the human immunoglobulin heavy constant domain epsilon P1 and P2pseudo-genes (IGHEP1 and IGHEP2). The IgG class is the most commonlyused for therapeutic purposes. In humans this class comprises subclassesIgG1, IgG2, IgG3 and IgG4. In mice this class comprises subclasses IgG1,IgG2a, IgG2b, IgG2c and IgG3.

The term “chimeric antibody” as used herein includes antibodies in whichthe variable region sequences are derived from one species and theconstant region sequences are derived from another species, such as anantibody in which the variable region sequences are derived from a mouseantibody and the constant region sequences are derived from a humanantibody.

The term “humanized antibody” or “humanized anti-OX40 antibody” as usedherein includes antibodies in which CDR sequences derived from thegermline of another mammalian species, such as a mouse, have beengrafted onto human framework sequences. Additional framework regionmodifications may be made within the human framework sequences as wellas within the CDR sequences derived from the germline of anothermammalian species.

The term “Fab” or “Fab region” as used herein includes the polypeptidesthat comprise the VH, CH1, VL, and CL immunoglobulin domains. Fab mayrefer to this region in isolation, or this region in the context of afull length antibody or antibody fragment.

The term “Fc” or “Fc region”, as used herein includes the polypeptidecomprising the constant region of an antibody excluding the firstconstant region immunoglobulin domain. Thus Fc refers to the last twoconstant region immunoglobulin domains of IgA, IgD, and IgG, and thelast three constant region immunoglobulin domains of IgE and IgM, andthe flexible hinge N-terminal to these domains. For IgA and IgM, Fc mayinclude the J chain. For IgG, Fc comprises immunoglobulin domains Cgamma 2 and C gamma 3 (Cγ2 and Cγ3) and the hinge between C gamma 1(Cγ1) and C gamma 2 (Cγ2). Although the boundaries of the Fc region mayvary, the human IgG heavy chain Fc region is usually defined to compriseresidues C226 or P230 to its carboxyl-terminus, wherein the numbering isaccording to the EU numbering system. For human IgG1 the Fc region isherein defined to comprise residue P232 to its carboxyl-terminus,wherein the numbering is according to the EU numbering system (Edelman GM et al., (1969) Proc Natl Acad Sci USA, 63(1): 78-85). Fc may refer tothis region in isolation or this region in the context of an Fcpolypeptide, for example an antibody.

The term “hinge” or “hinge region” or “antibody hinge region” hereinincludes the flexible polypeptide comprising the amino acids between thefirst and second constant domains of an antibody. The “hinge region” asreferred to herein is a sequence region of 6-62 amino acids in length,only present in IgA, IgD and IgG, which encompasses the cysteineresidues that bridge the two heavy chains. Structurally, the IgG CH1domain ends at EU position 220, and the IgG CH2 domain begins at residueEU position 237. Thus for IgG the antibody hinge is herein defined toinclude positions 221 (D221 in IgG1) to 231 (A231 in IgG1), wherein thenumbering is according to the EU numbering system (Edelman G M et al.,supra).

The term “parent antibody” or “parent immunoglobulin” as used hereinincludes an unmodified antibody that is subsequently modified togenerate a variant. Said parent antibody may be a naturally occurringantibody, or a variant or engineered version of a naturally occurringantibody. Parent antibody may refer to the antibody itself, compositionsthat comprise the parent antibody, or the amino acid sequence thatencodes it. By “parent anti-OX40 antibody” as used herein is meant anantibody or immunoglobulin that binds human OX40 and is modified togenerate a variant. By “corresponding murine antibody” as used herein ismeant a murine antibody or immunoglobulin that bind to human OX40 andthat can be modified to generate a variant, specifically the murineantibody 1D4 as disclosed herein.

The term “variant antibody” or “antibody variant” as used hereinincludes an antibody sequence that differs from that of a parentantibody sequence by virtue of at least one amino acid modificationcompared to the parent. The variant antibody sequence herein willpreferably possess at least about 80%, most preferably at least about90%, more preferably at least about 95% amino acid sequence identitywith a parent antibody sequence. Antibody variant may refer to theantibody itself, compositions comprising the antibody variant, or theamino acid sequence that encodes it.

The term “amino acid modification” herein includes an amino acidsubstitution, insertion, and/or deletion in a polypeptide sequence. By“amino acid substitution” or “substitution” herein is meant thereplacement of an amino acid at a particular position in a parentpolypeptide sequence with another amino acid. For example, thesubstitution R94K refers to a variant polypeptide, in this case a heavychain variable framework region variant, in which the arginine atposition 94 is replaced with a lysine. For the preceding example, 94Kindicates the substitution of position 94 with a lysine. For thepurposes herein, multiple substitutions are typically separated by aslash. For example, R94K/L78V refers to a double variant comprising thesubstitutions R94K and L78V. By “amino acid insertion” or “insertion” asused herein is meant the addition of an amino acid at a particularposition in a parent polypeptide sequence. For example, insert −94designates an insertion at position 94. By “amino acid deletion” or“deletion” as used herein is meant the removal of an amino acid at aparticular position in a parent polypeptide sequence. For example,R94—designates the deletion of arginine at position 94.

As used herein, the term “conservative modifications” or “conservativesequence modifications” is intended to refer to amino acid modificationsthat do not significantly affect or alter the binding characteristics ofthe antibody containing the amino acid sequence. Such conservativemodifications include amino acid substitutions, insertions anddeletions. Modifications can be introduced into an antibody of theinvention by standard techniques known in the art, such as site-directedmutagenesis and PCR-mediated mutagenesis.

Conservative amino acid substitutions are ones in which the amino acidresidue is replaced with an amino acid residue having a similar sidechain. Families of amino acid residues having similar side chains havebeen defined in the art. These families include amino acids with basicside chains (e.g., lysine, arginine, histidine), acidic side chains(e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g.,glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine,tryptophan), nonpolar side chains (e.g., alanine, valine, leucine,isoleucine, proline, phenylalanine, methionine), beta-branched sidechains (e.g., threonine, valine, isoleucine) and aromatic side chains(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one ormore amino acid residues within the CDR regions or within the frameworkregions of an antibody of the invention can be replaced with other aminoacid residues from the same side chain family and the altered antibody(variant antibody) can be tested for retained function.

For all human immunoglobulin heavy chain constant domains numbering isaccording to the “EU numbering system” (Edelman G M et al., (1969) ProcNatl Acad Sci USA, 63(1): 78-85). For the human kappa immunoglobulinlight chain constant domain (IGKC), numbering is according to the “EUnumbering system” (Edelman G M et al., supra).

For the human lambda immunoglobulin light chain constant domains (IGLC1,IGLC2, IGLC3, IGLC6, and IGLC7), numbering is according to the “Kabatnumbering system” (Kabat E A et al., (1991) Sequences of proteins ofimmunological interest. 5th Edition—US Department of Health and HumanServices, NIH publication no 91-3242) as described by Dariavach P etal., (1987) Proc Natl Acad Sci USA, 84(24): 9074-8 and Frangione B etal., (1985) Proc Natl Acad Sci USA, 82(10): 3415-9.

The term “variable domain” refers to the domains that mediatesantigen-binding and defines specificity of a particular antibody for aparticular antigen. In naturally occurring antibodies, theantigen-binding site consists of two variable domains that definespecificity: one located in the heavy chain (VH) and the other locatedin the light chain (VL). In some cases, specificity may exclusivelyreside in only one of the two domains as in single-domain antibodiesfrom heavy-chain antibodies found in camelids. The V regions are usuallyabout 110 amino acids long, and consist of relatively invariantstretches of amino acid sequence called framework regions (FRs) of 15-30amino acids separated by shorter regions of extreme variability called“hypervariable regions” that are 9-12 amino acids long. The variabledomains of native heavy and light chains comprise four FRs, largelyadopting a beat-sheet configuration, connected by three hypervariableregions, which form loops. The hypervariable regions in each chain areheld together in close proximity by FRs, and with the hypervariableregions from the other chain, contribute to the formation of the antigenbinding site of antibodies (see Kabat E A et al., supra). The term“hypervariable region” as used herein refers to the amino acid residuesof an antibody which are responsible for antigen binding. Thehypervariable region generally comprises amino acid residues from a“complementary determining region” or “CDR”, the latter being of highestsequence variability and/or involved in antigen recognition. For allvariable domains numbering is according to Kabat (Kabat E A et al.,supra).

A number of CDR definitions are in use and are encompassed herein. TheKabat definition is based on sequence variability and is the mostcommonly used (Kabat E A et al., supra). Chothia refers instead to thelocation of the structural loops (Chothia C & Lesk A M (1987) J. Mol.Biol. 196: 901-917). The AbM definition is a compromise between theKabat and the Chothia definitions and is used by Oxford Molecular's AbMantibody modelling software (Martin A C R et al., (1989) Proc. Natl.Acad. Sci. USA, 86: 9268-72; Martin A C R et al., (1991) MethodsEnzymol. 203: 121-153; Pedersen J T et al., (1992) Immunomethods, 1:126-136; Rees A R et al., (1996) In Sternberg M. J. E. (ed.), ProteinStructure Prediction. Oxford University Press, Oxford, 141-172). Thecontact definition has been recently introduced (MacCallum R M et al.,(1996) J. Mol. Biol. 262: 732-745) and is based on an analysis of theavailable complex structures available in the Protein Databank. Thedefinition of the CDR by IMGT®, the international ImMunoGeneTicsinformation System® (http://www.imgt.org) is based on the IMGT numberingfor all immunoglobulin and T cell receptor V-REGIONs of all species(IMGT®, the international ImMunoGeneTics information System®; Lefranc MP et al., (1991) Nucleic Acids Res. 27(1): 209-12; Ruiz M et al., (2000)Nucleic Acids Res. 28(1): 219-21; Lefranc M P (2001) Nucleic Acids Res.29(1): 207-9; Lefranc M P (2003) Nucleic Acids Res. 31(1): 307-10;Lefranc M P et al., (2005) Dev. Comp. Immunol. 29(3): 185-203; Kaas Q etal., (2007) Briefings in Functional Genomics & Proteomics, 6(4):253-64).

All Complementarity Determining Regions (CDRs) discussed in the presentinvention, are defined preferably according to IMGT®. The variabledomain residues for each of these CDRs are as follows (numberingaccording to Kabat E A, et al., supra): LCDR1: 27-32, LCDR2: 50-52,LCDR3: 89-97, HCDR1: 26-35, HCDR2: 51-57 and HCDR3: 93-102. The “non-CDRregion” of the VL region as used herein comprise the amino acidsequences: 1-26 (FR1), 33-49 (FR2), 53-88 (FR3), and 98—approximately107 (FR4). The “non-CDR region” of the VH region as used herein comprisethe amino acid sequences: 1-25 (FR1), 36-50 (FR2), 58-92 (FR3), and103—approximately 113 (FR4).

The CDRs of the present invention may comprise “extended CDRs” which arebased on the aforementioned definitions and have variable domainresidues as follows: LCDR1: 24-36, LCDR2: 46-56, LCDR3:89-97, HCDR1:26-36, HCDR2:47-65, HCDR3: 93-102. These extended CDRs are numbered aswell according to Kabat et al., supra. The “non-extended CDR region” ofthe VL region as used herein comprise the amino acid sequences: 1-23(FR1), 37-45 (FR2), 57-88 (FR3), and 98—approximately 107 (FR4). The“non-extended CDR region” of the VH region as used herein comprise theamino acid sequences: 1-25 (FR1), 37-46 (FR2), 66-92 (FR3), and103—approximately 113 (FR4).

The term “full length antibody” as used herein includes the structurethat constitutes the natural biological form of an antibody, includingvariable and constant regions. For example, in most mammals, includinghumans and mice, the full length antibody of the IgG class is a tetramerand consists of two identical pairs of two immunoglobulin chains, eachpair having one light and one heavy chain, each light chain comprisingimmunoglobulin domains VL and CL, and each heavy chain comprisingimmunoglobulin domains VH, CH1 (Cγ1), CH2 (Cγ2), and CH3 (Cγ3). In somemammals, for example in camels and llamas, IgG antibodies may consist ofonly two heavy chains, each heavy chain comprising a variable domainattached to the Fc region.

Antibody fragments include, but are not limited to, (i) the Fab fragmentconsisting of VL, VH, CL and CH1 domains, including Fab′ and Fab′-SH,(ii) the Fd fragment consisting of the VH and CH1 domains, (iii) the Fvfragment consisting of the VL and VH domains of a single antibody; (iv)the dAb fragment (Ward E S et al., (1989) Nature, 341: 544-546) whichconsists of a single variable, (v) F(ab′)2 fragments, a bivalentfragment comprising two linked Fab fragments (vi) single chain Fvmolecules (scFv), wherein a VH domain and a VL domain are linked by apeptide linker which allows the two domains to associate to form anantigen binding site (Bird R E et al., (1988) Science 242: 423-426;Huston J S et al., (1988) Proc. Natl. Acad. Sci. USA, 85: 5879-83),(vii) bispecific single chain Fv dimers (PCT/US92/09965), (viii)“diabodies” or “triabodies”, multivalent or multispecific fragmentsconstructed by gene fusion (Tomlinson I & Hollinger P (2000) MethodsEnzymol. 326: 461-79; WO94/13804; Holliger P et al., (1993) Proc. Natl.Acad. Sci. USA, 90: 6444-48) and (ix) scFv genetically fused to the sameor a different antibody (Coloma M J & Morrison S L (1997) NatureBiotechnology, 15(2): 159-163).

The term “effector function” as used herein includes a biochemical eventthat results from the interaction of an antibody Fc region with an Fcreceptor or ligand. Effector functions include FcγR-mediated effectorfunctions such as ADCC (antibody dependent cell-mediated cytotoxicity)and ADCP (antibody dependent cell-mediated phagocytosis), andcomplement-mediated effector functions such as CDC (complement dependentcytotoxicity). An effector function of an antibody may be altered byaltering, i.e. enhancing or reducing, preferably enhancing, the affinityof the antibody for an effector molecule such as an Fc receptor or acomplement component. Binding affinity will generally be varied bymodifying the effector molecule binding site, and in this case it isappropriate to locate the site of interest and modify at least part ofthe site in a suitable way. It is also envisaged that an alteration inthe binding site on the antibody for the effector molecule need notalter significantly the overall binding affinity but may alter thegeometry of the interaction rendering the effector mechanism ineffectiveas in non-productive binding. It is further envisaged that an effectorfunction may also be altered by modifying a site not directly involvedin effector molecule binding, but otherwise involved in performance ofthe effector function. By altering an effector function of an antibodyit may be possible to control various aspects of the immune response,e.g. enhancing or suppressing various reactions of the immune system,with possible beneficial effects in diagnosis and therapy.

As used herein, the term “OX40-mediated disorder” includes conditionssuch as allergy, asthma, COPD, rheumatoid arthritis, psoriasis anddiseases associated with autoimmunity and inflammation.

As used herein, the term “subject” includes any human or nonhumananimal. The term “nonhuman animal” includes all vertebrates, e.g.,mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats,horses, cows, chickens, amphibians, reptiles, etc. Preferably thesubject is human.

Anti-OX40 Antibodies

In a first aspect the present invention provides an antagonist antibodyor fragment thereof that binds to human OX40 comprising a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavychain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or aheavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3;and/or comprising a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acidsequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the aminoacid sequence of SEQ ID NO: 6.

In some embodiments the antagonist antibody or fragment thereof thatbinds to human OX40 comprises an extended heavy chain CDR1 comprisingthe amino acid sequence of SEQ ID NO: 13, and/or an extended heavy chainCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and/or anextended heavy chain CDR3 comprising the amino acid sequence of SEQ IDNO: 15; and/or comprises an extended light chain CDR1 comprising theamino acid sequence of SEQ ID NO: 16, and/or an extended light chainCDR2 comprising the amino acid sequence of SEQ ID NO: 17 and/or anextended light chain CDR3 comprising the amino acid sequence of SEQ IDNO: 18.

Preferably the antagonist antibody or fragment thereof that binds tohuman OX40 comprises a heavy chain CDR1 comprising the amino acidsequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acidsequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the aminoacid sequence of SEQ ID NO: 3 and/or a light chain CDR1 comprising theamino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising theamino acid sequence of SEQ ID NO: 5 and a light chain CDR3 comprisingthe amino acid sequence of SEQ ID NO: 6. More preferably the antagonistantibody or fragment thereof that binds to human OX40 comprises a heavychain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavychain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and aheavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3 anda light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, alight chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 anda light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

It is well known in the art that the CDR3 domain, independently from theCDR1 and/or CDR2 domain(s), alone can determine the binding specificityof an antibody for a cognate antigen and that multiple antibodies canpredictably be generated having the same binding specificity based on acommon CDR3 sequence. See, for example, Klimka A et al., (2000) Br. J.Cancer, 83(2): 252-260 (describing the production of a humanizedanti-CD30 antibody using only the heavy chain variable domain CDR3 ofmurine anti-CD30 antibody Ki-4); Beiboer S H et al., (2000) J. Mol.Biol. 296: 833-849 (describing recombinant epithelial glycoprotein-2(EGP-2) antibodies using only the heavy chain CDR3 sequence of theparental murine MOC-31 anti-EGP-2 antibody); Rader C et al., (1998)Proc. Natl. Acad. Sci. USA, 95: 8910-8915 (describing a panel ofhumanized anti-integrin αvβ3 antibodies using a heavy and light chainvariable CDR3 domain of a murine anti-integrin αvβ3 antibody LM609wherein each member antibody comprises a distinct sequence outside theCDR3 domain and capable of binding the same epitope as the parentalmurine antibody with affinities as high or higher than the parentalmurine antibody); Barbas C et al., (1994) J. Am. Chem. Soc. 116: 2161-62(disclosing that the CDR3 domain provides the most significantcontribution to antigen binding).

Accordingly, the present invention provides antibodies and fragmentsthereof that bind to human OX40 comprising one or more heavy and/orlight chain CDR3 domains, in particular comprising heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 3 and/or light chainCDR3 comprising the amino acid sequence of SEQ ID NO: 6, wherein theantibody is capable of binding to human OX40. Within some embodiments,such inventive antibodies comprising one or more heavy and/or lightchain CDR3 domain from a non-human antibody (a) are capable of competingfor binding with; (b) retain the functional characteristics; (c) bind tothe same epitope; and/or (d) have a similar binding affinity as thecorresponding parental non-human e.g. murine antibody.

In a further aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising a heavychain variable region sequence comprising the amino acid sequence of SEQID NO: 7. In another aspect the present invention provides an antagonistantibody or fragment thereof that binds to human OX40 comprising a lightchain variable region sequence comprising the amino acid sequence of SEQID NO: 8. In some embodiments the antagonist antibody or fragmentthereof that binds to human OX40 comprises a heavy chain variable regionsequence comprising the amino acid sequence of SEQ ID NO: 7 and a lightchain variable region sequence comprising the amino acid sequence of SEQID NO: 8.

In another aspect the present invention provides variants of anantagonist antibody or fragment thereof that binds to human OX40. Thusthe present invention provides antibodies or fragments thereof that havean amino acid sequence of the non-CDR regions of the heavy and/or lightchain variable region sequence which is at least 80% identical (havingat least 80% amino acid sequence identity) to the amino acid sequence ofthe non-CDR regions of the heavy and/or light chain variable regionsequence of the parent antagonist antibody of either the heavy or thelight chain e.g. of either the heavy and light variable region sequencesas in SEQ ID NO: 7 or SEQ ID NO: 8, respectively. As well antibodies orfragments thereof that have an amino acid sequence of the non-extendedCDR regions of the heavy and/or light chain variable region sequencewhich is at least 80% identical to the amino acid sequence of thenon-extended CDR regions of the heavy and/or light chain variable regionsequence of the parent antagonist antibody of either the heavy or thelight chain are provided by the present invention. Preferably the aminoacid sequence identity of the non-CDR regions or of the non-extended CDRregions of the heavy and/or light chain variable region sequence is atleast 85%, more preferably at least 90%, and most preferably at least95%, in particular 96%, more particular 97%, even more particular 98%,most particular 99%, including for example, 80%, 81%, 82%, 83%, 84%,85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99%, and 100%. Identity or homology with respect to an amino acidsequence is defined herein as the percentage of amino acid residues inthe candidate sequence that are identical with the antagonist antibodyor fragment thereof that binds to human OX40, after aligning thesequences and introducing gaps, if necessary, to achieve the maximumpercent sequence identity. Thus sequence identity can be determined bystandard methods that are commonly used to compare the similarity inposition of the amino acids of two polypeptides. Using a computerprogram such as BLAST or FASTA, two polypeptides are aligned for optimalmatching of their respective amino acids (either along the full lengthof one or both sequences or along a pre-determined portion of one orboth sequences). The programs provide a default opening penalty and adefault gap penalty, and a scoring matrix such as PAM250 (a standardscoring matrix; see Dayhoff M O et al., (1978) in Atlas of ProteinSequence and Structure, vol 5, supp. 3) can be used in conjunction withthe computer program. For example, the percent identity can becalculated as: the total number of identical matches multiplied by 100and then divided by the sum of the length of the longer sequence withinthe matched span and the number of gaps introduced into the longersequences in order to align the two sequences.

In some embodiments the present disclosure thus provides an antagonisticantibody or fragment thereof that binds to human OX40, wherein theantibody or fragment thereof comprises a heavy chain variable frameworkregion sequence which is at least 70% identical to the framework regionsequence of SEQ ID NOS: 19, 20, 21, 22 or 23 and/or a light chainvariable framework region sequence which is at least 60% identical tothe framework region sequence of SEQ ID NOS: 24, 25, 26, 27 and 28. Insome embodiments the present disclosure provides an antagonisticantibody or fragment thereof that binds to human OX40, wherein theantibody or fragment thereof comprises a heavy chain variable frameworkregion sequence which is at least 74% identical to the framework regionsequence of SEQ ID NO: 19 and/or a light chain variable framework regionsequence which is at least 65% identical to the framework regionsequence of SEQ ID NO: 24.

In another aspect the present invention provides an antagonisticantibody or fragment thereof that binds to human OX40 comprising theheavy and or light chain CDRs as described supra and further comprisinga heavy chain variable framework region that is the product of orderived from a human gene selected from the group consisting ofIGHV2-70*10 (SEQ ID NO: 19), IGHV2-70*01 (SEQ ID NO: 20), IGHV2-70*13(SEQ ID NO: 21), IGHV2-5*09 (SEQ ID NO: 22), and IGHV2-70*11 (SEQ ID NO:23), preferably a heavy chain variable framework region that is theproduct of or derived from human gene IGHV2-70*10 (SEQ ID NO: 19). Theheavy chain variable framework region may comprise one or more (e.g.,one, two, three and/or four) heavy chain framework region sequences(e.g., framework 1 (FW1), framework 2 (FW2), framework 3 (FW3) and/orframework 4 (FW4)) present in the product of or derived from those humangenes. Preferably the heavy chain variable region framework comprisesFW1, FW2 and/or FW3, more preferably FW1, FW2 and FW3 present in theproduct of or derived from a human gene selected from the groupconsisting of IGHV2-70*10 (SEQ ID NO: 19), IGHV2-70*01 (SEQ ID NO: 20),IGHV2-70*13 (SEQ ID NO: 21), IGHV2-5*09 (SEQ ID NO: 22), and IGHV2-70*11(SEQ ID NO: 23). Heavy chain framework region sequences as used hereininclude FW1 (position 1 to position 25), FW2 (position 36 to position49), FW3 (position 66 to position 94) and FW 4 (position 103 to position113), wherein the amino acid position is indicated utilizing thenumbering system set forth in Kabat.

In some embodiments the present disclosure provides an antibody orfragment thereof, wherein the antibody or fragment thereof comprises aheavy chain variable framework region that is the product of or derivedfrom human gene IGHV2-70*10 (SEQ ID NO: 19) and wherein the heavy chainvariable framework region comprises at least one amino acid modificationfrom the corresponding heavy chain variable framework region of thecorresponding murine antibody.

In some embodiments the present disclosure provides an antibody orfragment thereof comprising a heavy chain sequence comprising the aminoacid sequence of SEQ ID NO: 32 and wherein the heavy chain variableframework region comprises at least one amino acid modification from thecorresponding heavy chain variable framework region of the correspondingmurine antibody.

Preferably the amino acid modification comprises an amino acidsubstitution at amino acid position selected from the group consistingof 23, 35b, 48, 50, 60, and 62, more preferably at amino acid positionsselected from the group consisting of 23, 35b, 50, 60 and 62, mostpreferred at amino acid position 35b, wherein the amino acid position ofeach group member is indicated according to the Kabat numbering.Specifically the amino acid modification comprises an amino acidsubstitution selected from the group consisting of 23S, 35bG, 48L, 50H,60N, and 62A, preferably an amino acid substitution selected from thegroup consisting of T23S, S35bG, 148L, R5OH, S60N and S62A, whereasS35bG is the most preferred amino acid substitution wherein the aminoacid position of each group member is indicated according to the Kabatnumbering.

In another aspect the present invention provides an antagonisticantibody or fragment thereof that binds to human OX40 comprising a lightchain variable framework region that is the product of or derived from ahuman gene selected from the group consisting of IGKV3-11*01 (SEQ ID NO:24), IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01 (SEQ ID NO: 26),IGKV3-11*02 (SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO: 28), preferablya light chain variable framework region that is the product of orderived from human gene IGKV3-11*01 (SEQ ID NO: 24). The light chainvariable region framework region may comprise one or more (e.g., one,two, three and/or four) light chain framework region sequences (e.g.,framework 1 (FW1), framework 2 (FW2), framework 3 (FW3) and/or framework4 (FW4)) present in the product of or derived from those human genes.Preferably the light chain variable region framework comprises FW1, FW2and/or FW3, more preferably FW1, FW2 and FW3 present in the product ofor derived from a human gene selected from the group consisting ofV3-11*01 (SEQ ID NO: 24), IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01 (SEQID NO: 26), IGKV3-11*02 (SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO: 28).Light chain framework region sequences as used herein include FW1(position 1 to position 23), FW2 (position 35 to position 49), FW3(position 57 to position 88) and FW 4 (position 98 to position 108),wherein the amino acid position is indicated utilizing the numberingsystem set forth in Kabat.

In some embodiments the present disclosure provides an antibody orfragment thereof comprising a light chain variable framework region thatis the product of or derived from human gene IGKV3-11*01 (SEQ ID NO: 24)and wherein the light chain variable framework region comprises at leastone amino acid modification from the corresponding framework region ofthe light chain variable region of the corresponding murine antibody.

In some embodiments the present disclosure provides an antibody orfragment thereof comprising a light chain sequence comprising the aminoacid sequence of SEQ ID NO: 39 and wherein the light chain variableframework region of the light chain sequence comprises at least oneamino acid modification from the corresponding light chain variableframework region of the corresponding murine antibody.

Preferably the amino acid modification comprises an amino acidsubstitution at amino acid position selected from the group consistingof 1, 33, 34, 46, 47, 54, 56, and 71 and/or a deletion at amino acidposition 31, more preferably an amino acid substitution at amino acidposition selected from the group consisting of 33, 34, 46, 47, 54, 56,and 71 and/or a deletion at amino acid position 31, most preferably anamino acid substitution at amino acid position 46 and/or 47, wherein theamino acid position of each group member is indicated according to theKabat numbering. Specifically the amino acid modification comprises anamino acid substitution selected from the group consisting of 1Q, 33M,34H, 46P, 47W, 54L, 56S, and 71Y, and/or a deletion at T31, preferablyan amino acid substitution selected from the group consisting of a 1Q,33M, 34H, 46P, 47W, 54L, 56S and 71Y, more preferably an amino acidsubstitution selected from the group consisting of 33M, 34H, 46P, 47Wand 71Y, whereas 46P, 47W are particularly preferred, wherein the aminoacid position of each group member is indicated according to the Kabatnumbering.

In some embodiments the antagonistic antibody or fragment thereof thatbinds to human OX40 comprises a heavy chain variable framework regionthat is the product of or derived from a human gene selected from thegroup consisting of V2-70*10 (SEQ ID NO: 19), V2-70*01 (SEQ ID NO: 20),V2-70*13 (SEQ ID NO: 21), V2-5*09 (SEQ ID NO: 22), and V2-70*11 (SEQ IDNO: 23) and a light chain variable framework region that is the productof or derived from a human gene selected from the group consisting ofV3-11*01 (SEQ ID NO: 24), IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01 (SEQID NO: 26), IGKV3-11*02 (SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO: 28),preferably a heavy chain variable framework region that is the productof or derived from human gene V2-70*10 (SEQ ID NO: 19), and a lightchain variable framework region that is the product of or derived fromhuman gene V3-11*01 (SEQ ID NO: 24). As well combinations of heavy chainvariable framework regions which are present in the product of orderived from different human genes mentioned supra and/or of light chainvariable region framework regions which are present in the product of orderived from different human genes mentioned supra are encompassed bythe present invention.

Germline DNA sequences for human heavy and light chain variable regiongenes can be found in the “VBase” human germline sequence database(available on the Internet at www.mrccpe. cam.ac.uk/vbase), as well asin Kabat E A et al., supra; Tomlinson I M et al., (1992) J. Mol. Biol.227: 776-798 and Cox J P L et al., (1994) Eur. J. Immunol. 24: 827-836.As another example, the germline DNA sequences for human heavy and lightchain variable region genes can be found in the Genbank database.

In another aspect, the present disclosure also provides an antagonistantibody or fragment thereof that binds to human OX40, wherein at leastone of the heavy chain CDRs and/or at least one of the light chain CDRscomprises at least one amino acid modification. Site-directedmutagenesis or PCR-mediated mutagenesis can be performed to introducethe modification(s) and the effect on antibody binding, or otherfunctional property of interest, can be evaluated in in vitro or in vivoassays. Preferably conservative modifications are introduced. Themodification(s) may be amino acid substitutions, additions or deletions,but are preferably substitutions. Typically, no more than five,preferably no more than four, more preferably no more than three, evenmore preferably no more than two, most preferably no more than one aminoacid modifications are performed within a CDR region.

In certain embodiments, framework sequences can be used to engineervariable regions to produce variant antibodies. Variant antibodies ofthe invention include those in which modifications have been made toframework residues within VH and/or VK, e.g. to improve the propertiesof the antibody. Typically such framework modifications are made todecrease the immunogenicity of the antibody. For example, one approachis to “backmutate” one or more framework residues to the correspondingmurine sequence or to “backmutate” one or more framework residues to acorresponding germline sequence.

Thus in a further aspect the present disclosure provides an antagonisticantibody or fragment thereof that binds to human OX40, wherein at leastone of the framework region sequences of the heavy chain variable regionof the humanized antibody or fragment thereof comprises at least oneamino acid modification from the corresponding framework region of theheavy chain variable region of the corresponding murine antibody.Preferably the amino acid modification is an amino acid substitution.Typically, no more than six, preferably no more than five, preferably nomore than four, more preferably no more than three, even more preferablyno more than two, most preferably no more than one amino acidmodifications are performed within a framework region. In someembodiments the present disclosure provides an antagonistic antibody orfragment thereof that binds to human OX40, wherein the amino acidmodification of the framework regions of the heavy chain variable regioncomprise an amino acid substitution at amino acid position selected fromthe group consisting of 23, 35b, 48, 50, 60 and 62, and wherein theamino acid position of each group member is indicated according to theKabat numbering. Preferred amino acid substitution of the frameworkregions of the heavy chain variable region are at amino acid positionsselected from the group consisting of 23, 35b, 50, 60 and 62. Morepreferred amino acid substitutions of the framework regions of the heavychain variable region are selected from the group consisting of 23S,35bG, 48L, 50H, 60N and 62A, whereas 35bG is the most preferred aminoacid substitution of the framework regions of the heavy chain variableregion.

The present disclosure also provides an antagonistic antibody orfragment thereof that binds to human OX40, wherein at least one of theframework region sequences of the light chain variable region of thehumanized antibody or fragment thereof comprises at least one amino acidmodification from the corresponding framework region of the light chainvariable region of the corresponding murine antibody. Preferably theamino acid modification is an amino acid substitution and/or an aminoacid deletion. Typically, no more than six, preferably no more thanfive, preferably no more than four, more preferably no more than three,even more preferably no more than two, most preferably no more than oneamino acid modifications are performed within a framework region. Insome embodiments the present disclosure provides a humanized antibody orfragment thereof, wherein the amino acid modification of the frameworkregions of the light chain variable region sequence comprises an aminoacid substitution at amino acid position selected from the groupconsisting of 1, 33, 34, 46, 47, 54, 56 and 71 and/or a deletion atamino acid position 31. More preferred amino acid modifications of theframework regions of the light chain variable region sequence comprise adeletion at Y31 and/or a substitution selected from the group consistingof a 1Q, 33M, 34H, 46P, 47W, 54L, 56S and 71Y, and wherein the aminoacid position of each group member is indicated according to the Kabatnumbering. Most preferred amino acid modifications of the frameworkregions of the light chain variable region sequence comprise a deletionat T31 and/or a substitution selected from the group consisting of 33M,34H, 46P, 47W and 71Y, whereas 46P, and/or L47W are particularlypreferred. In some embodiments the humanized antibody or fragmentthereof of the present invention may comprise amino acid modificationsof the framework regions of the heavy chain variable region sequence asset out above and amino acid modifications of the framework regions ofthe light chain variable region sequence as set out above.

The present disclosure also provides an antagonistic antibody orfragment thereof that binds to human OX40 that comprises a heavy chainvariable region selected from the group consisting of SEQ ID NOS: 29,58, 59, 77, 78, 79 and 80, preferably selected from the group consistingof SEQ ID NOS: 58, 59, 79 and 80 and more preferably from the groupconsisting of SEQ ID NOS: 58 and 59. The present disclosure alsoprovides an antagonistic antibody or fragment thereof that binds tohuman OX40 that comprises a light chain variable region selected fromthe group consisting of SEQ ID NOS: 30, 60, 81, 82, 83, 84, 85, 86, 87,88, and 89, preferably selected from the group consisting of SEQ ID NOS:60, 86, 87 and 89, more preferably SEQ ID NO: 60. In some embodimentsthe antagonistic antibody or fragment thereof that binds to human OX40comprises a heavy chain variable region selected from the groupconsisting of SEQ ID NOS: 29, 58, 59, 77, 78, 79 and 80, and a lightchain variable region selected from the group consisting of SEQ ID NOS:30, 60, 81, 82, 83, 84, 85, 86, 87, 88, and 89. Given that each of theseheavy and light chain variable region sequences can bind to human OX40,the heavy and light chain variable region sequences can be “mixed andmatched” to create anti-OX40 binding molecules of the invention. OX40binding of such “mixed and matched” antibodies can be tested using thebinding assays described e.g. in the Examples.

In some embodiments the antagonistic antibody or fragment thereof thatbinds to human OX40 comprises a heavy chain variable region selectedfrom the group consisting of SEQ ID NOS: 58 and 59, and a light chainvariable region selected from the group consisting of SEQ ID NOS: 60 and89. In more preferred embodiments the antagonistic antibody or fragmentthereof that binds to human OX40 comprises a heavy chain variable regioncomprising the amino acid sequence of SEQ ID NO: 58 and a light chainvariable region comprising the amino acid sequence of SEQ ID NO: 60, aheavy chain variable region comprising the amino acid sequence of SEQ IDNO: 58 and a light chain variable region comprising the amino acidsequence of SEQ ID NO: 89, a heavy chain variable region comprising theamino acid sequence of SEQ ID NO: 59 and a light chain variable regioncomprising the amino acid sequence of SEQ ID NO: 60, or a heavy chainvariable region comprising the amino acid sequence of SEQ ID NO: 59 anda light chain variable region comprising the amino acid sequence of SEQID NO: 89. Most preferred is an antagonistic antibody or fragmentthereof that binds to human OX40 comprising a heavy chain variableregion selected from the group consisting of SEQ ID NOS: 58 and 59, anda light chain variable region comprising the amino acid sequence of SEQID NO: 60.

The present disclosure also provides an antagonistic antibody orfragment thereof that binds to human OX40 that comprises a heavy chainsequence selected from the group consisting of SEQ ID NOS: 32, 33, 34,35, 36, 37 and 38, preferably selected from the group consisting of SEQID NOS: 35, 36, 37 and 38 and more preferably from the group consistingof SEQ ID NOS: 37 and 38. The present disclosure also provides anantagonistic antibody or fragment thereof that binds to human OX40 thatcomprises a light chain sequence selected from the group consisting ofSEQ ID NOS: 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 and 49, preferablyselected from the group consisting of SEQ ID NOS: 45, 46, 47 and 49,more preferably SEQ ID NO: 47. In some embodiments the antagonisticantibody or fragment thereof that binds to human OX40 comprises a heavychain sequence selected from the group consisting of SEQ ID NOS: 32, 33,34, 35, 36, 37 and 38, and a light chain sequence selected from thegroup consisting of SEQ ID NOS: 39, 40, 41, 42, 43, 44, 45, 46, 47, 48and 49. Given that each of these heavy and light chain variable regionsequences can bind to human OX40, the heavy and light chain variableregion sequences can be “mixed and matched” to create anti-OX40 bindingmolecules of the invention. OX40 binding of such “mixed and matched”antibodies can be tested using the binding assays described e.g. in theExamples.

In some embodiments the antagonistic antibody or fragment thereof thatbinds to human OX40 comprises a heavy chain sequence selected from thegroup consisting of SEQ ID NOS: 37 and 38, and a light chain sequenceselected from the group consisting of SEQ ID NOS: 47 and 49. In morepreferred embodiments the antagonistic antibody or fragment thereof thatbinds to human OX40 comprises a heavy chain sequence comprising theamino acid sequence of SEQ ID NO: 37 and a light chain sequencecomprising the amino acid sequence of SEQ ID NO: 47, a heavy chainsequence comprising the amino acid sequence of SEQ ID NO: 37 and a lightchain sequence comprising the amino acid sequence of SEQ ID NO: 49, aheavy chain sequence comprising the amino acid sequence of SEQ ID NO: 38and a light chain sequence comprising the amino acid sequence of SEQ IDNO: 47, or a heavy chain sequence comprising the amino acid sequence ofSEQ ID NO: 38 and a light chain sequence comprising the amino acidsequence of SEQ ID NO: 49. Most preferred is an antagonistic antibody orfragment thereof that binds to human OX40 comprising a heavy chainsequence selected from the group consisting of SEQ ID NOS: 37 and 38,and a light chain sequence comprising the amino acid sequence of SEQ IDNO: 47.

In one embodiment of the present disclosure, the antagonist antibody orfragment thereof is a murine antibody, chimeric antibody or a humanizedantibody, preferably a humanized antibody, more preferably a monoclonalmurine antibody, a monoclonal chimeric antibody or a monoclonalhumanized antibody.

The present disclosure also provides a monovalent antibody or fragmentthereof that binds to human OX40, i.e. an antibody which consists of asingle antigen binding arm. The present disclosure also provides afragment of a antibody that binds to human OX40 selected from the groupconsisting of Fab, Fab′, Fab′-SH, Fd, Fv, dAb, F(ab′)2, scFv, bispecificsingle chain Fv dimers, diabodies, triabodies and scFv genetically fusedto the same or a different antibody. Preferred fragments are scFv,bispecific single chain Fv dimers and diabodies. The present disclosurealso provides a full length antibody that binds to human OX40.

The present disclosure also provides an antibody or fragment thereofthat binds to human OX40 which further comprises a heavy and/or lightconstant region in particular a human heavy and/or a human lightconstant region. Human heavy constant regions may be selected from thegroup of human immunoglobulins consisting of IgG1 (IGHG1), IgG2 (IGHG2),IgG3 (IGHG3), IgG4 (IGHG4), IgA1 (IGHA1), IgA2 (IGHA2), IgM (IGHM), IgD(IGHD), or IgE (IGHE), whereas the human heavy constant region IgG, inparticular IgG1 (IGHG1) is preferred. Human light constant region may beselected from the group of human immunoglobulins consisting of kappa orlambda constant regions, whereas human kappa constant region ispreferred. In a preferred embodiment the antagonistic antibody orfragment thereof that binds to human OX40 comprises a human IgG1 (IGHG1)heavy constant domain and a human light kappa constant domain.

In addition or alternative to modifications made within the frameworkregions or CDR regions, antibodies of the invention may be engineered toinclude modifications within the Fc region, typically to alter one ormore functional properties of the antibody, such as serum half-life,complement fixation, Fc receptor binding, and/or antigen-dependentcellular cytotoxicity. Furthermore, an antibody of the invention may bechemically modified (e.g., one or more chemical moieties can be attachedto the antibody) or be modified to alter its glycosylation. Each ofthese embodiments is described in further detail below. Modificationswithin the Fc region as outlined below are according to the EU numberingof residues in the Fc region. In one embodiment, the hinge region of CH1is modified such that the number of cysteine residues in the hingeregion is altered, e.g., increased or decreased. This approach isdescribed further in U.S. Pat. No. 5,677,425 by Bodmer et al. The numberof cysteine residues in the hinge region of CH1 is altered to, forexample, facilitate assembly of the light and heavy chains or toincrease or decrease the stability of the antibody. In anotherembodiment, the Fc hinge region of an antibody is mutated to decreasethe biological half life of the antibody. More specifically, one or moreamino acid mutations are introduced into the CH2-CH3 domain interfaceregion of the Fc-hinge fragment such that the antibody has impairedStaphylococcal protein A (SpA) binding relative to native Fc-hingedomain SpA binding. This approach is described in further detail in U.S.Pat. No. 6,165,745 by Ward et al. In another embodiment, the antibody ismodified to increase its biological half life. Various approaches arepossible. For example, one or more of the following mutations can beintroduced: T252L, T254S, T256F, as described in U.S. Pat. No. 6,277,375to Ward. Alternatively, to increase the biological half life, theantibody can be altered within the CH1 or CL region to contain a salvagereceptor binding epitope taken from two loops of a CH2 domain of an Fcregion of an IgG, as described in U.S. Pat. Nos. 5,869,046 and 6,121,022by Presta et al. In a further embodiment Fc region is altered byreplacing at least one amino acid residue with a different amino acidresidue to alter the effector function(s) of the antibody. For example,one or more amino acids selected from amino acid residues 234, 235, 236,237, 297, 318, 320 and 322 can be replaced with a different amino acidresidue such that the antibody has an altered affinity for an effectorligand but retains the antigen-binding ability of the parent antibody.The effector ligand to which affinity is altered can be, for example, anFc receptor or the Cl component of complement. This approach isdescribed in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260,both by Winter et al. In another example, one or more amino acidsselected from amino acid residues 329, 331 and 322 can be replaced witha different amino acid residue such that the antibody has altered C1qbinding and/or reduced or abolished complement dependent cytotoxicity(CDC). This approach is described in further detail in U.S. Pat. No.6,194,551 by Idusogie et al. In another example, one or more amino acidresidues within amino acid positions 231 to 238 in the N-terminal regionof the CH2 domain are altered to thereby alter the ability of theantibody to fix complement. This approach is described further in PCTPublication WO94/29351 by Bodmer et al. In yet another example, the Fcregion is modified to increase the ability of the antibody to mediateantibody dependent cellular cytotoxicity (ADCC) and/or to increase theaffinity of the antibody for an Fcγ receptor by modifying one or moreamino acids at the following positions: 238, 239, 248, 249, 252, 254,255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285,286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 309,312, 315, 320, 322, 324, 326, 327, 329, 330, 331, 333, 334, 335, 337,338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430,434, 435, 437, 438 or 439. This approach is described further in PCTPublication WO00/42072 by Presta.

The present disclosure also provides an antagonistic antibody orfragment thereof that binds to human OX40 comprising human heavy and/orlight constant regions, wherein the human heavy constant regioncomprises an isotypic variant comprising the CH1 region, the hingeregion, the CH2 region and CH3 region from human IgG4 (IGHG4) andwherein the hinge region comprises a substitution of serine at position228 to proline. Preferably the humanized antibody comprising theisotypic variant is a full length antibody. A particular preferredhumanized antibody or fragment thereof that binds to human OX40comprising an isotypic variant comprising the CH1 from human IgG4(IGHG4), the hinge from human IgG4 (IGHG4), having S228P substitutionand the CH2 and CH3 from human IgG4 (IGHG4) comprises a heavy chainsequence comprising the amino acid sequence of SEQ ID NO: 57 and a lightchain sequence comprising the amino acid sequence of SEQ ID NO: 47. Ithas been found that the isotypic variant exhibits no Fc-mediatedcytotoxicity mechanisms such as ADCC compared to an antagonisticantibody or fragment thereof that binds to human OX40 which comprises ahuman heavy constant region from human IgG1 (IGHG1) (which is usually anative human IgG1), i.e. as compared to an antagonistic antibody orfragment thereof that binds to human OX40 that only differs from theisotypic variant with regard to the modified heavy constant region.

The present disclosure also provides an antagonistic antibody orfragment thereof that binds to human OX40 which comprises a human IgG Fcregion, wherein the mature core carbohydrate structure attached to thehuman IgG Fc region lacks fucose (referred herein alternatively as “nonfucosylated”). Preferably the antibody comprises a human IgG1 (IGHG1) Fcregion, wherein the mature core carbohydrate structure attached to thehuman IgG1 (IGHG1) Fc region lacks fucose. More preferred is afull-length antibody comprising a human IgG1 (IGHG1) Fc region, whereinthe mature core carbohydrate structure attached to the human IgG1(IGHG1) Fc region lacks fucose. It is known from WO03/035835 that lackof fucose in the mature core carbohydrate structure attached to thehuman IgG Fc region may enhance ADCC. Thus in a further embodiment theantagonistic antibody or fragment thereof of the present disclosurecomprises a human IgG1 (IGHG1) Fc region, wherein the mature corecarbohydrate structure attached to the human IgG1 (IGHG1) Fc regionlacks fucose, whereas the antibody lacking fucose exhibits enhanced ADCCcompared to the parent humanized antibody or fragment thereof notlacking fucose. Methods to generate antibodies which lack fucose are,for example (a) use of an engineered or mutant host cell that isdeficient in fucose metabolism such that it has a reduced ability (or isunable to) fucosylate proteins expressed therein; (b) culturing cellsunder conditions which prevent or reduce fucosylation; (c)post-translational removal of fucose (e.g. with a fucosidase enzyme);(d) post-translational addition of the desired carbohydrate, e.g. afterrecombinant expression of a non-glycosylated glycoprotein; or (e)purification of the glycoprotein so as to select for product which isnot fucosylated. Preferably used are methods described in Example 14 ofWO10/095,031 e,g. methods described in Longmore et al., (1982)Carbohydr. Res. 365-92 or in Imai-Nishiya et al., (2007), BMCBiotechnol. 7: 84.

Also provided by the present invention is an antagonist antibody orfragment thereof that binds to human OX40 and which binds to the sameepitope as the antibody comprising the heavy chain variable sequencecomprising the amino acid sequence of SEQ ID NO. 7 and/or the lightchain variable sequence comprising the amino acid sequence of SEQ ID NO.8. Also provided by the present invention is a specific region orepitope of human OX40, in particular of the human OX40 receptorextracellular domain, which is bound by an antibody provided by thepresent invention, in particular by an antibody comprising the heavychain variable sequence comprising the amino acid sequence of SEQ ID NO.7 and/or the light chain variable sequence comprising the amino acidsequence of SEQ ID NO. 8. This specific region or epitope of the humanOX40 polypeptide can be identified by any suitable epitope mappingmethod known in the art in combination with any one of the antibodiesprovided by the present invention. Examples of such methods includescreening peptides of varying lengths derived from OX40 for binding tothe antibody of the present invention with the smallest fragment thatcan specifically bind to the antibody containing the sequence of theepitope recognised by the antibody. The OX40 peptides may be producedsynthetically or by proteolytic digestion of the OX40 polypeptide.Peptides that bind the antibody can be identified by, for example, massspectrometric analysis. In another example, NMR spectroscopy or X-raycrystallography can be used to identify the epitope bound by an antibodyof the present invention. Once identified, the epitopic fragment whichbinds an antibody of the present invention can be used, if required, asan immunogen to obtain additional antagonist antibodies which bind thesame epitope.

Anti-OX40 Antibody Properties

Standard assays to evaluate the binding ability of the antibodies towarde.g. human OX40 are known in the art, including for example, ELISAs,BIAcore®, Western blots, RIAs, and flow cytometry analysis. Suitableassays are described in detail in the Examples. The binding kinetics(e.g., binding affinity like KD) of the antibodies also can be assessedby standard assays known in the art, such as by Scatchard or BIAcore®system analysis. The relative binding affinity K_(i) can be assessed bystandard competition assays known in the art.

In a further aspect the present invention provides antagonisticantibodies or fragment thereof that bind to human OX40 and which block aHuman Mixed Lymphocyte Reaction (MLR) in a dose dependent manner to ahigher degree than recombinant humanized antibody efalizumab.Recombinant humanized antibody efalizumab binds to the CD11a subunit oflymphocyte function-associated antigen 1. MLR can be carried out andmeasured according to Example 3.

In a further aspect the present invention provides antagonist antibodiesor fragment thereof that bind to human OX40 and which are also able torecognise cynomologus monkey OX40. Binding of an antagonistic anti-OX40antibody to both human and cynomologus peripheral blood monocuclearcells (PBMC) can be carried out and measured according to Example 4 andshown in FIG. 3. The antibody was found to recognise OX40 expressed onthe surface of human and cynomologus monkey activated lymphocytesindicating that this antibody has cross-reactive properties.

In a further aspect the present invention provides antagonisticantibodies or fragment thereof that bind to human OX40, in particularhuman OX40 in isolated form, with an affinity (K_(D)) of 500 nM or less,preferably 200 nM or less, more preferably 150 nM or less, morepreferably 120 nM or less, even more preferably 110 nM or less e.g.measured by Surface Plasmon Resonance (SPR) on a BIAcore® instrument (GEHealthcare Europe GmbH, Glattbrugg, Switzerland) by capturing theantibody on a protein-A coupled CM5 research grade sensor chip (GEHealthcare Europe GmbH, Glattbrugg, Switzerland; BR-1000-14) with arecombinant monovalent human OX40 receptor extracellular domain (SEQ IDNO: 11) used as analyte as detailed in Examples 5 and 6 and asillustrated in FIG. 4. “Monovalent” as used herein in relation toaffinity measurements using OX40 receptor refers to a human OX40receptor domain, like the extracellular domain, not artificiallydimerized or multimerized as it would be e.g. if the domain would beamino-terminally fused to an immunoglobulin Fc portion. In a preferredaspect, the present invention provides a humanized antibody or fragmentthereof that retains at least 75% of the OX40 binding affinity (K_(D))of the corresponding chimeric antibody. Preferably, the humanizedantibody or fragment thereof binds human OX40 with equivalent affinityto the corresponding chimeric antibody. By “equivalent affinity” ismeant an affinity value that is within a range of ±10% of the OX40binding affinity of the corresponding chimeric antibody. Morepreferably, the present invention provides a humanized antibody orfragment thereof that binds human OX40 with a higher affinity than thecorresponding chimeric antibody. In a preferred aspect of the presentinvention, antagonistic antibodies or fragment thereof that bind tohuman OX40 are provided that have a binding affinity (K_(D)) of 110 nMor less, preferably 100 nM or less, more preferably 90 nM or less, morepreferably 80 nM or less, even more preferably 70 nM or less e.g.measured by Surface Plasmon Resonance (SPR) on a BIAcore® instrument (GEHealthcare Europe GmbH, Glattbrugg, Switzerland) by capturing theantibody on a protein-A coupled CM5 research grade sensor chip (GEHealthcare Europe GmbH, Glattbrugg, Switzerland; BR-1000-14) with arecombinant monovalent human OX40 receptor extracellular domain (SEQ IDNO: 11) used as analyte as detailed in Examples 5 and 6 and asillustrated in FIG. 4.

A further aspect of the present invention provides antagonisticantibodies or fragments thereof that bind to human OX40 and which havegood thermal stability. In a preferred embodiment, an antagonistichumanized antibody or fragment thereof that binds to human OX40 has aFAB fragment thermostability temperature greater than 70° C., preferablygreater than 75° C., more preferably greater than 80° C. and even morepreferably greater than 85° C. For analysis of FAB fragmentthermostability differential scanning calorimetry measurements are used,whereas a mid-point melting temperature of the FAB fragment in contextof a full-length IgG is identified. These kind of calorimetricmeasurements are known to the skilled person and can be carried outaccording to e.g. Garber & Demarest (2007), BBRC, 355: 751-7, as furtherdescribed in Example 6 and shown in FIG. 6.

In a further aspect the present invention describes antagonisticantibodies or fragments thereof that bind to an epitope on the humanOX40 extracellular region. As described in Example 7 and shown in FIG.7, one or more of the four domains of the OX40 extracellular region wereexchanged between human and rat sequences and Fc fusion proteinsgenerated. A binding ELISA was then performed to test the reactivity ofan antagonistic humanised antibody on the human OX40 extracellularregion, rat OX40 extracellular region and four human-rat chimericproteins. Thus the present invention provides an antagonistic antibodyor fragment thereof which maps within the second domain of human OX40extracellular region.

The present invention also provides antagonistic antibodies or fragmentsthereof which can be used to suppress immune reactions. The effect of anantagonistic humanized anti-OX40 antibody was tested in a MLR (seeExample 8) used as an in vitro model of alloreactive T cell activationand proliferation (O'Flaherty E et al., (2000) Immunology, 100(3):289-99; DuPont B & Hansen J A (1976) Adv. Immunol. 23: 107-202). PBMCsfrom two unreleated donors were mixed, resulting in the activation of Tcells and a proliferation of T lymphocytes. In addition, three differentformats of the antagonistic humanized anti-OX40 antibody were tested inthis assay: an IgG1 (IGHG1) format, a non fucosylated IgG1 (IGHG1)format and an

IgG4 (IGHG4) format, to further determine the contribution of cytotoxicmechanisms such as ADCC on the inhibition of MLR. The antagonistichumanized anti-OX40 antibody efficiently inhibited MLR in two differentindividuals (responders) with EC50 values of approximately 100 ng/mL.However the results showed a difference depending on the format of theantibody used. In the first individual (responder 1), T cell reactivitywas efficiently inhibited by the IgG1 (IGHG1) and IgG4 (IGHG4) antibodyformats indicating that the cytotoxic mechanisms are not critical forthis individual. For the second individual (responder 2) the IgG1(IGHG1) format achieved more than 60% inhibition, whereas the IgG4(IGHG4) format only poorly blocked the MLR. In both individuals, the nonfucosylated IgG1 (IGHG1) format was very effective at inhibiting MLR.These results indicate that blocking OX40 activation may be sufficientin some individuals to inhibit MLR but this effect can be greatlyenhanced by additional cytotoxic mechanisms. Therefore for the treatmentof patients suffering from OX40 mediated disorders, where the disorderappears to be independent of the patients' OX40 costimulatory statuse.g. patients with low OX40 expression levels, administration of anantagonistic antibody or fragment thereof that binds human OX40 andwhich has enhanced cytotoxic mechanisms may be particularly effective. Apreferred embodiment of the present invention provides an antagonistichumanized antibody that binds to human OX40 for the treatment of apatient suffering from an OX40 mediated disorder. Furthermore, thepatient may have low expression levels of OX40. Preferably theantagonistic humanized antibody that binds to human OX40 comprises anIgG1 (IGHG1) region. More preferably the antagonistic humanized antibodythat binds to human OX40 comprises a non fucosylated IgG1 region.

In a further aspect of the present invention, the effect of anantagonistic antibody or fragment thereof was demonstrated in axenogeneic graft versus host reaction, in which SCID mice werereconstituted with human PBMCs. This reaction provides a model for theallogenic graft versus host disease (GVHD) observed after bone marrowtransplant in human patients. In this model, human PBMCs and Tlymphocytes in particular, launch a strong response against the mousehost cells which gives rise to severe inflammatory symptoms. Asdescribed in Example 9 and shown in FIG. 9 and Table 10, an antagonistichumanized antibody that binds to human OX40 potently suppressed the GVHDreaction at a dose of 1 mg/kg. Surprisingly, this antibody demonstrateda better efficacy than Enbrel®, a recognised therapy for GVHD (Xhaard Aet al., (2011) Bull. Cancer, 98(8): 889-99; Simpson D (2001) ExpertOpin. Pharmacother. 2(7): 1109-17). Therefore, in a preferredembodiment, the present invention provides an antagonistic antibody orfragment thereof that binds to human OX40 and which is effective in thetreatment of GVHD. Preferably, administration of the antibody to asubject results in a four-fold improvement in survival median (days)compared to the administration of vehicle. More preferably,administration of the antibody to a subject results in a two-foldimprovement in survival median (days) compared to the administration ofEnbrel®. The present invention therefore provides an antagonisticantibody or fragment therefore that binds to human OX40 that is moreeffective than Enbrel® in treating a patient with GVHD and/or atsurpressing GVHD. In addition, it has been reported that agonisticanti-OX40 binding antibodies worsen GVHD in allogenic mouse GVHD models(Valzasina B et al., (2005) Blood, 105(7): 2845-51; Blazar B R et al.,(2003) Blood, 101(9): 3741-8), therefore it can be concluded fromExample 9, that antagonistic antibodies and fragments thereof of thepresent invention show no agonistic effects on binding human OX40, sinceno worsening of the GVHD was observed in the model. Therefore, thepresent invention provides a humanized antibody or fragment thereforethat binds to human OX40 that does not show agonistic activity onbinding.

Nucleic Acids, Vectors and Host Cells

The present disclosure also provides isolated nucleic acids encoding theantibodies and fragments thereof that bind to human OX40, vectors andhost cells comprising the nucleic acid or the vector. The nucleic acidsmay be present in whole cells, in a cell lysate, or in a partiallypurified or substantially pure form. A nucleic acid is “isolated” or“rendered substantially pure” when purified away from other cellularcomponents or other contaminants, e.g., other cellular nucleic acids orproteins, by standard techniques, including alkaline/SDS treatment, CsClbanding, column chromatography, agarose gel electrophoresis and otherswell known in the art, see e.g. F. Ausubel, et al., ed. (1987) CurrentProtocols in Molecular Biology, Greene Publishing and WileyInterscience, New York. A nucleic acid of the invention can be, forexample, DNA or RNA and may or may not contain intron sequences. In apreferred embodiment, the nucleic acid is a cDNA molecule.

Nucleic acids of the invention can be obtained using standard molecularbiology techniques e.g. cDNAs encoding the light and heavy chains of theantibody or encoding VH and VL segments can be obtained by standard PCRamplification or cDNA cloning techniques. For antibodies obtained froman immunoglobulin gene library (e.g., using phage display techniques),one or more nucleic acids encoding the antibody can be recovered fromthe library. The methods of introducing exogenous nucleic acid into hostcells are well known in the art, and will vary with the host cell used.Techniques include but are not limited to dextran-mediated transfection,calcium phosphate precipitation, calcium chloride treatment,polyethylenimine mediated transfection, polybrene mediated transfection,protoplast fusion, electroporation, viral or phage infection,encapsulation of the polynucleotide(s) in liposomes, and directmicroinjection of the DNA into nuclei. In the case of mammalian cells,transfection may be either transient or stable.

Preferred nucleic acids molecules of the invention are those encodingthe heavy chain sequence selected from the group consisting of SEQ IDNOS: 32, 33, 34, 35, 36, 37 and 38 and/or the light chain sequenceselected from the group consisting of SEQ ID NOS: 39, 40, 41, 42, 43,44, 45, 46, 47, 48 and 49. Preferred nucleic acids molecules of theinvention are those encoding the heavy chain variable region selectedfrom the group consisting of SEQ ID NOS: 29, 58, 59, 77, 78, 79 and 80and/or the light chain variable region selected from the groupconsisting of SEQ ID NOS: 30, 60, 81, 82, 83, 84, 85, 86, 87, 88, and89.

Preferred nucleic acids molecules of the invention are those encodingthe light chain variable region of SEQ ID NO: 8 and/or the heavy chainvariable region of SEQ ID NO: 7, e.g. DNA encoding the heavy chainvariable region comprising the nucleic acid sequence of SEQ ID NO: 9and/or DNA encoding the light chain variable region comprising thenucleic acid sequence of SEQ ID NO: 10. More preferred nucleic acidmolecules of the invention are those encoding the heavy chain variableregion of SEQ ID NOS: 58 or 59 and/or the light chain variable region ofSEQ ID NO: 60, e.g. DNA encoding the heavy chain variable regioncomprising the nucleic acid sequence of SEQ ID NOS: 61 or 62 and/or DNAencoding the light chain variable region comprising the nucleic acidsequence of SEQ ID NO: 63, which are most preferred.

Once DNA fragments encoding VH and VL segments are obtained, these DNAfragments can be further manipulated by standard recombinant DNAtechniques, for example to convert the variable region genes tofull-length antibody chain genes, or to fragments genes corresponding tothe fragments described supra like Fab fragment genes or to a scFv gene.In these manipulations, a VL- or VH-encoding DNA fragment is operativelylinked to another DNA fragment encoding another protein, such as anantibody constant region or a flexible linker. The term “operativelylinked”, as used in this context, is intended to mean that the two DNAfragments are joined such that the amino acid sequences encoded by thetwo DNA fragments remain in-frame. The isolated DNA encoding the VHregion can be converted to a full-length heavy chain gene by operativelylinking the VH-encoding DNA to another DNA molecule encoding heavy chainconstant regions (CH1, CH2 and CH3). The sequences of human heavy chainconstant region genes are known in the art (see e.g., Kabat E A et al.,supra) and DNA fragments encompassing these regions can be obtained bystandard PCR amplification. The heavy chain constant region can be anIgG1 (IGHG1), IgG2 (IGHG2), IgG3 (IGHG3), IgG4 (IGHG4), IgA1 (IGHA1),IgA2 (IGHA2), IgM (IGHM), IgD (IGHD), or IgE (IGHE) constant region, butmost preferably is an IgG1 (IGHG1) constant region. For a Fab fragmentheavy chain gene, the VH-encoding DNA can be operatively linked toanother DNA molecule encoding only the heavy chain CH1 constant region.The isolated DNA encoding the VL region can be converted to afull-length light chain gene (as well as a Fab light chain gene) byoperatively linking the VL-encoding DNA to another DNA molecule encodingthe light chain constant region, CL. The sequences of human light chainconstant region genes are known in the art (see e.g., Kabat E A et al.,supra.) and DNA fragments encompassing these regions can be obtained bystandard PCR amplification. In preferred embodiments, the light chainconstant region can be a kappa or lambda constant region, preferably akappa constant region. To create a scFv gene, the VH- and VL-encodingDNA fragments are operatively linked to another fragment encoding aflexible linker, e.g., encoding the amino acid sequence (Gly4-Ser)₃,such that the VH and VL sequences can be expressed as a contiguoussingle-chain protein, with the VL and VH regions joined by the flexiblelinker (see e.g., Bird R E et al., (1988) Science, 242: 423-426; HustonJ S et al., (1988) Proc. Natl. Acad. Sci. USA, 85: 5879-83; McCafferty Jet al., (1990) Nature, 348: 552-554). Various techniques have beendeveloped for the production of antibody fragments of antibodies.Traditionally, these fragments were derived via proteolytic digestion ofintact antibodies (see, e.g., Morimoto K et al., (1992) J. Biochem. &Biophysical Methods, 24: 107-117 and Brennan M et al., (1985) Science,229: 81-3). However, these fragments can now be produced directly byrecombinant host cells. For example, the antibody fragments can beisolated from the antibody phage libraries discussed above.Alternatively, Fab′-SH fragments can be directly recovered from E. coliand chemically coupled to form F(ab′)₂ fragments (Carter P et al.,(1992) Bio/Technology, 10: 163-167). According to another approach,F(ab′)2 fragments can be isolated directly from recombinant host cellculture. Other techniques for the production of antibody fragments willbe apparent to the skilled practitioner. In other embodiments, theantibody of choice is a single-chain Fv fragment (scFv), see e.g. WO1993/16185; U.S. Pat. No. 5,571,894 and U.S. Pat. No. 5,587,458. Theantibody fragment may also be a “linear antibody”, e.g., as described inU.S. Pat. No. 5,641,870, for example.

The nucleic acids that encode the antibodies of the present inventionmay be incorporated into a vector, preferably an expression vector inorder to express the protein. A variety of expression vectors may beutilized for protein expression. Expression vectors may compriseself-replicating extra-chromosomal vectors or vectors which integrateinto a host genome. Expression vectors are constructed to be compatiblewith the host cell type. Thus vectors, preferably expression vectors,which find use in the present invention include but are not limited tothose which enable protein expression in mammalian cells, bacteria,insect cells, yeast, and in in vitro systems. As is known in the art, avariety of expression vectors are available, commercially or otherwise,that may find use in the present invention for expressing antibodies.

Expression vectors typically comprise a protein operably linked withcontrol or regulatory sequences, selectable markers, any fusionpartners, and/or additional elements. By “operably linked” herein ismeant that the nucleic acid is placed into a functional relationshipwith another nucleic acid sequence. The term “regulatory sequence” isintended to include promoters, enhancers and other expression controlelements (e.g., polyadenylation signals) that control the transcriptionor translation of the antibody chain genes. Such regulatory sequencesare described, for example, in Goeddel (Gene Expression Technology,Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990)).Generally, these expression vectors include transcriptional andtranslational regulatory nucleic acid operably linked to the nucleicacid encoding the antibody, and are typically appropriate to the hostcell used to express the protein. In general, the transcriptional andtranslational regulatory sequences may include promoter sequences,ribosomal binding sites, transcriptional start and stop sequences,translational start and stop sequences, and enhancer or activatorsequences. As is also known in the art, expression vectors typicallycontain a selection gene or marker to allow the selection of transformedhost cells containing the expression vector. Selection genes are wellknown in the art and will vary with the host cell used. For example,typically the selectable marker gene confers resistance to drugs, suchas G418, hygromycin or methotrexate, on a host cell into which thevector has been introduced. Preferred selectable marker genes includethe dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells withmethotrexate selection/amplification) and the neo gene (for G418selection).

Suitable host cells for cloning or expressing the DNA in the vectorsherein are prokaryote, yeast, or higher eukaryote cells. Suitableprokaryotes for this purpose include eubacteria, including gram-negativeor gram-positive organisms, for example, Enterobacteriaceae such asEscherichia, e.g., E. coli, Enterobacter, Klebsiella, Proteus,Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratiamarcescans, and Shigella, as well as Bacilli such as B. subtilis and B.licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces.Suitable E. coli cloning hosts include E. coli 294 (ATCC 31,446), E.coli B, E. coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325). Inaddition to prokaryotes, eukaryotic microbes such as filamentous fungior yeast are suitable cloning or expression hosts. Saccharomycescerevisiae, or common baker's yeast, is the most commonly used amonglower eukaryotic host microorganisms. However, a number of other genera,species, and strains are commonly available and useful, such asSchizosaccharoriyces pombe; Kluyveromyces hosts including K. lactis, K.fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC24,178), K. WaItH (AJCC 56,500), K. drosopmarum (ATCC 36,906), K.thermotolerans, or K. marxianusyarrowia (EP402226); Pichia pastoris(EP183070); Candida; Trichoderma reesia (EP244234); Neurospora crassa;Schwanniomyces such as Schwanniomyces occidentalis; and filamentousfungi including Neurospora, Penicillium, Tolypocladium, or Aspergillushosts such as A. nidulans or A. niger.

Suitable host cells for the expression of the antibodies of theinvention are derived from multicellular organisms. Examples ofinvertebrate cells include plaril and insect cells. Numerous baculoviralstrains and variants and corresponding permissive insect host cells fromhosts such as Spodoptera frugiperda (caterpillar), Aedes augypti(mosquito), Aedes albopictus (mosquito), Drosophila melanogaster(fruitfly) and Bombyx mori have been identified. A variety of viralstrains for transfection are publicly available, for example, the L-1variant of Autographa californica NPV and the Bm-5 strain of Bombyx moriNPV, and such viruses may be used, particularly for transfection ofSpodoptera frugiperda cells. Plant cell cultures of cotton, corn,potato, soybean, petunia, tomato, and tobacco can also be utilized ashosts.

Host cells for expressing the recombinant antibodies of the inventionare preferably mammalian host cells which include Chinese Hamster Ovary(CHO cells) (including dhfr⁻ CHO cells, described in Urlaub G & Chasin LA (1980) Proc. Natl. Acad. Sci, USA, 77: 4216-4220, used with a DHFRselectable marker, e.g., as described in Kaufman R J & Sharp P A (1982)J. Mol. Biol, 159: 601-621), NSO myeloma cells, COS cells and SP2 cells.In particular, for use with NSO myeloma cells, another preferredexpression system is the GS gene expression system disclosed in WO87/04462 (to Wilson), WO 89/01036 (to Bebbington) and EP338841 (toBebbington). When recombinant antibody genes are introduced intomammalian host cells, the antibodies are produced by culturing the hostcells for a period of time sufficient to allow for expression of theantibody in the host cells or, more preferably, for secretion of theantibody into the culture medium in which the host cells are grown. Hostcells useful for producing antibodies that bind to human OX40 may becultured in a variety of media. Commercially available media such asHam's F10 (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), MinimalEssential Medium (MEM; Sigma-Aldrich Chemie GmbH), RPMI-1640(Sigma-Aldrich Chemie GmbH, Basel, Switzerland), and Dulbecco's ModifiedEagle's Medium ((DMEM; Sigma-Aldrich Chemie GmbH) are suitable forculturing the host cells. Antibodies can be recovered from the culturemedium using standard protein purification methods.

Antibodies may be operably linked to a fusion partner to enabletargeting of the expressed protein, purification, screening, display,and the like. Fusion partners may be linked to the antibody sequence viaa linker sequences. The linker sequence will generally comprise a smallnumber of amino acids, typically less than ten, although longer linkersmay also be used. Typically, linker sequences are selected to beflexible and resistant to degradation. As will be appreciated by thoseskilled in the art, any of a wide variety of sequences may be used aslinkers. For example, a common linker sequence comprises the amino acidsequence GGGGS. A fusion partner may be a targeting or signal sequencethat directs antibody and any associated fusion partners to a desiredcellular location or to the extracellular media. As is known in the art,certain signalling sequences may target a protein to be either secretedinto the growth media, or into the periplasmic space, located betweenthe inner and outer membrane of the cell. A fusion partner may also be asequence that encodes a peptide or protein that enables purificationand/or screening. Such fusion partners include but are not limited topolyhistidine tags (His-tags) (for example H6 and H10 or other tags foruse with Immobilized Metal Affinity Chromatography (IMAC) systems (e.g.Ni⁺² affinity columns)), GST fusions, MBP fusions, Strep-tag, the BSPbiotinylation target sequence of the bacterial enzyme BirA, and epitopetags which are targeted by antibodies (for example c-myc tags,flag-tags, and the like). As will be appreciated by those skilled in theart, such tags may be useful for purification, for screening, or both.

Construction and Production of Antibodies

Antibodies generated against the OX40 polypeptide may be obtained byimmunisation of an animal i.e. by administering the polypeptides to ananimal, preferably a non-human animal, using well-known and routineprotocols, see for example Handbook of Experimental Immunology (Weir D M(ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986).Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows,camels or pigs may be immunized. However, mice, rabbits, pigs and ratsin particular mice are generally most suitable. Antibodies can beproduced as well by recombinant DNA techniques known to the skilledperson. In additional antibodies can be produced by enzymatic orchemical cleavage of naturally occurring antibodies. Humanizedantibodies of the present invention may be constructed by transferringone or more CDRs or portions thereof from VH and/or VL regions from anon-human animal (e.g., mouse) to one or more framework regions fromhuman VH and/or VL regions. Optionally, human framework residues thuspresent in the VH and/or VL regions may be replaced by correspondingnon-human (e.g., mouse) residues when needed or desired for decreasingimmunogenicity of the antibody and/or maintaining binding affinity.Optionally, non-human amino acid residues present in the CDRs may bereplaced with human residues. Chimeric or humanized antibodies of thepresent invention can be prepared based on the sequence of a non-humanmonoclonal antibody prepared as described above. DNA encoding the heavyand light chain immunoglobulins can be obtained from the non-humanhybridoma of interest and engineered to contain non-murine (e.g., human)immunoglobulin sequences using standard molecular biology techniques.For example, to create a chimeric antibody, murine variable regions canbe linked to human constant regions using methods known in the art (seee.g., U.S. Pat. No. 4,816,567 to Cabilly et al). To create a humanizedantibody, murine CDR regions can be inserted into a human frameworkusing methods known in the art (see e.g., U.S. Pat. No. 5,225,539 toWinter, and U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370to Queen et al).

Humanized antibodies of the present invention may be constructed whereinthe human acceptor molecule for the heavy chain variable region isselected based on homology considerations between potential acceptormolecule variable regions and the heavy chain variable region of themurine antibody. Germline candidate human acceptor molecules arepreferred to reduce potential immunogenicity. Germline databases aremade up of antibody sequences that read through the end of the heavychain FW3 region and partially into the CDR3 sequence. For selection ofa FW4 region, databases of mature antibody sequences which have beenderived from the selected germline molecule can be searched or antibodysequences which have been derived from the selected germline moleculefrom a human donor can be used. Human acceptor molecules are preferablyselected from the same heavy chain class as the murine donor molecule,and of the same canonical structural class of the variable region of themurine donor molecule. Secondary considerations for selection of thehuman acceptor molecule for the heavy chain variable region eludehomology in CDR length between the murine donor molecule and the humanacceptor molecule. Human acceptor antibody molecules are preferablyselected by homology search to the V-BASE database, although otherdatabases such as the Kabat and the public NCBI databases may be used aswell.

Humanized antibodies of the present invention may be constructed whereinthe human acceptor molecule for the light chain variable region isselected based on homology considerations between potential acceptormolecule variable regions and with the light chain variable region ofthe murine antibody. Germline candidate human acceptor molecules arepreferred to reduce potential immunogenicity. Germline databases aremade up of antibody sequences that read through the end of the heavychain FW3 region and partially into the CDR3 sequence. For selection ofa FW4 region, databases of mature antibody sequences which have beenderived from the selected germline molecule can be searched or antibodysequences which have been derived from the selected germline moleculefrom a human donor can be used. Human acceptor molecules are preferablyselected from the same light chain class as the murine donor molecule,and of the same canonical structural class of the variable region of themurine donor molecule. Secondary considerations for selection of thehuman acceptor molecule for the light chain variable region includehomology in CDR length between the murine donor molecule and the humanacceptor molecule. Human acceptor antibody molecules are preferablyselected by homology searches to the V-BASE database, and otherdatabases such as the Kabat and the public NCBI databases may be used aswell. Methods for humanizing a nonhuman antibody are described herein,including in Example 6, below.

The present invention provides a method of producing an antagonisticantibody or fragment thereof that binds to human OX40 comprisingculturing a host cell comprising an isolated nucleic acid encoding theantagonistic antibody or fragment thereof that binds to human OX40 or avector comprising an isolated nucleic acid encoding the antagonisticantibody or fragment thereof that binds to human OX40 so that thenucleic acid is expressed and the antibody produced. Preferably theantibody is isolated. For host cells, nucleic acids and vectors, theones described above can be used. Expression of the nucleic acids can beobtained by, e.g. a combination of recombinant DNA techniques and genetransfection methods as is well known in the art (e.g., Morrison S(1985) Science 229: 1202) and as further outlined above. For example, toexpress the antibodies, or antibody fragments thereof, DNAs encodingpartial or full-length light and heavy chains, can be obtained bystandard molecular biology techniques (e.g., PCR amplification or cDNAcloning using a hybridoma that expresses the antibody of interest) andthe DNAs can be inserted into vectors such as expression vectors. Theexpression vector and expression control sequences are chosen to becompatible with the expression host cell used. The antibody light chaingene and the antibody heavy chain gene can be inserted into separatevector or, more typically, both genes are inserted into the sameexpression vector. The antibody genes are inserted into the expressionvector by standard methods (e.g., ligation of complementary restrictionsites on the antibody gene fragment and vector, or blunt end ligation ifno restriction sites are present). The light and heavy chain variableregions of the antibodies described herein can be used to createfull-length antibody genes of any antibody isotype by inserting theminto expression vectors already encoding heavy chain constant and lightchain constant regions of the desired isotype such that the VH segmentis operatively linked to the CH1 segment(s) within the vector and the VKsegment is operatively linked to the CK segment within the vector.

Characterization and Purification of Anti-OX40 antibodies

Screening for antibodies can be performed using assays to measurebinding to human OX40 and/or assays to measure the ability to block thebinding of OX40 to its ligand, OX40L. An example of a binding assay isan ELISA, in particular, using a fusion protein of human OX40 and humanFc, which is immobilized on plates, and employing a conjugated secondaryantibody to detect anti-OX40 antibody bound to the fusion protein. Anexample of a blocking assay is a flow cytometry based assay measuringthe blocking of OX40 ligand fusion protein binding to OX40 on human CD4cells. A fluorescently labelled secondary antibody is used to detect theamount of OX40 ligand fusion protein binding to the cell. This assay islooking for a reduction in signal as the antibody in the supernatantblocks the binding of ligand fusion protein to OX40. A further exampleof a blocking assay is an assay where the blocking of costimulation ofnaive human T cells mediated by OX40 ligand fusion protein coated to aplate is measured by measuring thymidine incorporation. As an assay forevaluating the functional activity of anti-OX40 antibodies e.g. thereduction of T cell activation the human Mixed Lymphocyte Reaction (MLR)as described in Examples 3 and 8 can be used. Antibodies of the presentinvention may be isolated or purified in a variety of ways known tothose skilled in the art. Standard purification methods includechromatographic techniques, including ion exchange, hydrophobicinteraction, affinity, sizing or gel filtration, and reversed-phase,carried out at atmospheric pressure or at high pressure using systemssuch as FPLC and HPLC. Purification methods also includeelectrophoretic, immunological, precipitation, dialysis, andchromatofocusing techniques. Ultrafiltration and diafiltrationtechniques, in conjunction with protein concentration, are also useful.To purify OX40 antibodies, selected host cells can be grown in e.g.spinner-flasks for monoclonal antibody purification. Supernatants can befiltered and concentrated before affinity chromatography with proteinA-sepharose (Pharmacia, Piscataway, N.J.). Eluted antibodies can bechecked by gel electrophoresis and high performance liquidchromatography to ensure purity. A preferred antibody of the presentinvention is thus an isolated and/or purified antibody that binds tohuman OX40.

Immunoconjugates

In another aspect, the present invention provides an antagonist OX40antibody or a fragment thereof that binds to human OX40, linked to atherapeutic agent, such as a cytotoxin, a drug (e.g., animmunosuppressant) or a radiotoxin. Such conjugates are referred toherein as “immunoconjugates”. Immunoconjugates that include one or morecytotoxins are referred to as “immunotoxins.” A cytotoxin or cytotoxicagent includes any agent that is detrimental to (e.g., kills) cells.Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide,emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine,colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione,mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone,glucocorticoids, procaine, tetracaine, lidocaine, propranolol, andpuromycin and analogs or homologs thereof. Therapeutic agents alsoinclude, for example, antimetabolites (e.g., methotrexate,6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracildecarbazine), alkylating agents (e.g., mechlorethamine, thioepachlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU),cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycinC, and cis-dichlorodiamine platinum (II) (DDP) cisplatin),anthracyclines (e.g., daunorubicin (formerly daunomycin) anddoxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin),bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents(e.g., vincristine and vinblastine). Other examples of therapeuticcytotoxins that can be linked to an antibody of the invention includeduocarmycins, calicheamicins, maytansines and auristatins, andderivatives thereof. An example of a calicheamicin antibody conjugate iscommercially available (Mylotarg(R); American Home Products). Cytotoxinscan be linked to antibodies of the invention using linker technologyavailable in the art. Examples of linker types that have been used toconjugate a cytotoxin to an antibody include, but are not limited to,hydrazones, thioethers, esters, disulfides and peptide-containinglinkers. A linker can be chosen that is, for example, susceptible tocleavage by low pH within the lysosomal compartment or susceptible tocleavage by proteases, such as proteases preferentially expressed intumor tissue such as cathepsins (e.g., cathepsins B, C, D). For furtherdiscussion of types of cytotoxins, linkers and methods for conjugatingtherapeutic agents to antibodies, see also Saito G et al., (2003) Adv.Drug Deliv. Rev. 55: 199-215; Trail P A et al., (2003) Cancer Immunol.Immunother. 52: 328-337; Payne G (2003) Cancer Cell, 3: 207-212; Allen TM (2002) Nat. Rev. Cancer, 2: 750-763; Pastan I & Kreitman R J (2002)Curr. Opin. Investig. Drugs, 3: 1089-1091; Senter P D & Springer C J,(2001) Adv. Drug Deliv. Rev. 53: 247-264. Antibodies of the presentinvention also can be linked to a radioactive isotope to generatecytotoxic radiopharmaceuticals, also referred to asradioimmunoconjugates. Examples of radioactive isotopes that can beconjugated to antibodies for use diagnostically or therapeuticallyinclude, but are not limited to, iodine¹³¹, indium¹¹¹, yttrium⁹⁰ andlutetium¹⁷⁷. Methods for preparing radioimmunconjugates are establishedin the art. Examples of radioimmunoconjugates are commerciallyavailable, including Zevalin® (EDEC Pharmaceuticals) and Bexxar® (CorixaPharmaceuticals) and similar methods can be used to prepareradioimmunoconjugates using the antibodies of the invention. Theantibody immunoconjugates of the invention can be used to modify a givenbiological response, and the drug moiety is not to be construed aslimited to classical chemical therapeutic agents. For example, the drugmoiety may be a protein or polypeptide possessing a desired biologicalactivity. Such proteins may include, for example, an enzymaticallyactive toxin, or active fragment thereof, such as abrin, ricin A,pseudomonas exotoxin, or diphtheria toxin; a protein such as tumornecrosis factor or interferon-γ; or, biological response modifiers suchas, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2(“IL-2”), interleukin-6 (“IL-6”), granulocyte macrophage colonystimulating factor (“GM-CSF”), granulocyte colony stimulating factor(“G-CSF”), or other growth factors.

Techniques for linking such therapeutic agents to antibodies are wellknown, see, e.g., Amon et al., “Monoclonal Antibodies ForImmunotargeting Of Drugs In Cancer Therapy”, in Monoclonal AntibodiesAnd Cancer Therapy, Reisfeld et al., (eds.), pp. 243-56 (Alan R. Liss,Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery”, inControlled Drug Delivery (2nd Ed.), Robinson et al., (eds.), pp. 623-53(Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of CytotoxicAgents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84:Biological And Clinical Applications, Pinchera et al., (eds.), pp.475-506 (1985); “Analysis, Results, And Future Prospective Of TheTherapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, inMonoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al.,(eds.), pp. 303-16 (Academic Press 1985), and Thorpe P E & Ross W C(1982) Immunol. Rev. 62: 119-58.

In another aspect, the present invention provides an antagonist OX40antibody or a fragment thereof that binds to human OX40, administeredtogether with a therapeutic agent, such as a cytotoxin, a drug (e.g., animmunosuppressant) or a radiotoxin.

Pharmaceutical Compositions

In another aspect, the present invention provides a composition, e.g., apharmaceutical composition, comprising the antagonist antibody orfragment thereof, of the present invention, and a pharmaceuticallyacceptable carrier. Such compositions may include one or a combinationof (e.g., two or more different) antibodies, and/or immunoconjugates ofthe invention and/or a therapeutic agent, such as a cytotoxin, a drug(e.g., an immunosuppressant) or a radiotoxin as described supra. Forexample, a pharmaceutical composition of the invention can comprise acombination of antibodies (or immunoconjugates) that bind to differentepitopes on the target antigen or that have complementary activities.Pharmaceutical compositions of the invention also can be administered incombination therapy, i.e., combined with other agents. For example, thecombination therapy can include an antagonist OX40 antibody of thepresent invention combined with at least one other anti-inflammatory orimmunosuppressant agent.

As used herein, “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like that arephysiologically compatible. Preferably, the carrier is suitable forintravenous, intramuscular, subcutaneous, parenteral, spinal orepidermal administration (e.g., by injection or infusion). Depending onthe route of administration, the active compound, i.e., antibody orimmunoconjugate, may be coated in a material to protect the compoundfrom the action of acids and other natural conditions that mayinactivate the compound. Pharmaceutically acceptable carriers includesterile aqueous solutions or dispersions and sterile powders for theextemporaneous preparation of sterile injectable solutions ordispersion. The use of such media and agents for pharmaceutically activesubstances is known in the art. Except insofar as any conventional mediaor agent is incompatible with the active compound, use thereof in thepharmaceutical compositions of the invention is contemplated.Supplementary active compounds can also be incorporated into thecompositions.

In another aspect, the present invention provides a compositioncomprising an immunoconjugate comprising the antagonist antibody orfragment thereof that binds to human OX40 linked to a therapeutic agentand a pharmaceutically acceptable carrier. Immunoconjugates andtherapeutic agents which can be used are as described supra.

In another aspect, the present invention provides a compositioncomprising the antagonist antibody or fragment thereof of the presentinvention which further comprises another pharmaceutically active agent.Preferably the another pharmaceutically active agent is one or more of:a) another antagonist to human OX40, b) an analgesic agent and c) animmune suppressive agent e.g. a glucocorticoid such as prednisone.

A pharmaceutical composition of the invention may also include apharmaceutically acceptable antioxidant. Examples of pharmaceuticallyacceptable antioxidants include: (1) water soluble antioxidants, such asascorbic acid, cysteine hydrochloride, sodium bisulfate, sodiummetabisulfite, sodium sulfite and the like; (2) oil—solubleantioxidants, such as ascorbyl palmitate, butylated hydroxyanisole(BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate,alpha-tocopherol, and the like; and (3) metal chelating agents, such ascitric acid, ethylenediamine tetraacetic-acid (EDTA), sorbitol, tartaricacid, phosphoric acid, and the like. Examples of suitable aqueous andnonaqueous carriers that may be employed in the pharmaceuticalcompositions of the invention include water, ethanol, polyols (such asglycerol, propylene glycol, polyethylene glycol, and the like), andsuitable mixtures thereof, vegetable oils, such as olive oil, andinjectable organic esters, such as ethyl oleate. Proper fluidity can bemaintained, for example, by the use of coating materials, such aslecithin, by the maintenance of the required particle size in the caseof dispersions, and by the use of surfactants. These compositions mayalso contain adjuvants such as preservatives, wetting agents,emulsifying agents and dispersing agents. Prevention of presence ofmicroorganisms may be ensured both by sterilization procedures, supra,and by the inclusion of various antibacterial and antifungal agents, forexample, paraben, chlorobutanol, phenol sorbic acid, and the like. Itmay also be desirable to include isotonic agents, such as sugars, sodiumchloride, and the like into the compositions. In addition, prolongedabsorption of the injectable pharmaceutical form may be brought about bythe inclusion of agents which delay absorption such as aluminummonostearate and gelatin.

Therapeutic and Other Uses

The antagonist antibodies of the present invention have numerous invitro and in vivo diagnostic and therapeutic utilities involving thediagnosis and treatment of OX40 mediated disorders. For example, thesemolecules can be administered to cells in culture, in vitro or ex vivo,or to human subjects, e.g., in vivo, to treat, prevent and to diagnose avariety of OX40-mediated disorders. Preferred subjects are human andinclude patients having disorders mediated by OX40 activity (OX40mediated disorders). The antagonist antibodies of the present inventioncan be effective in treating patients independent of their OX40costimulatory status. More preferred subjects are human and includepatients expressing a low level of OX40.

A “patient” for the purposes of the present invention includes bothhumans and other animals, preferably mammals and most preferably humans.Thus the antibodies of the present invention have both human therapy andveterinary applications. The term “treatment” or “treating” in thepresent invention is meant to include therapeutic treatment, as well asprophylactic, or suppressive measures for a disease or disorder. Thus,for example, successful administration of an antibody prior to onset ofthe disease results in treatment of the disease. As another example,successful administration of an antibody after clinical manifestation ofthe disease to combat the symptoms of the disease comprises treatment ofthe disease. “Treatment” and “treating” also encompasses administrationof an antibody after the appearance of the disease in order to eradicatethe disease. Successful administration of an antibody after onset andafter clinical symptoms have developed, with possible abatement ofclinical symptoms and perhaps amelioration of the disease, comprisestreatment of the disease. Those “in need of treatment” include mammalsalready having the disease or disorder, as well as those prone to havingthe disease or disorder, including those in which the disease ordisorder is to be prevented.

In a particular embodiment, the antagonist antibodies are used in vivoto treat, prevent or diagnose a variety of OX40-mediated disorders. Thusthe invention provides a method for treating an OX40 mediated disorderin a subject, the method comprising administering to the subject atherapeutically effective amount of the antagonist antibody or fragmentthereof. Exemplary OX40 mediated disorders include infections (viral,bacterial, fungal and parasitic), endotoxic shock associated withinfection, arthritis, rheumatoid arthritis, asthma, chronic obstructivepulmonary disease (COPD), pelvic inflammatory disease, Alzheimer'sDisease, inflammatory bowel disease, Crohn's disease, ulcerativecolitis, Peyronie's Disease, coeliac disease, gallbladder disease,Pilonidal disease, peritonitis, psoriasis, vasculitis, surgicaladhesions, stroke, Type I Diabetes, lyme disease, arthritis,meningoencephalitis, autoimmune uveitis, immune mediated inflammatorydisorders of the central and peripheral nervous system such as multiplesclerosis, lupus (such as systemic lupus erythematosus) andGuillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis,fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathicthrombocytopenic purpura, Meniere's disease, pemphigus, primary biliarycirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis,pancreatitis, trauma (surgery), graft-versus-host disease (GVHD),transplant rejection, cardiovascular disease including ischaemicdiseases such as myocardial infarction as well as atherosclerosis,intravascular coagulation, bone resorption, osteoporosis,osteoarthritis, periodontitis, hypochlorhydia and neuromyelitis optica.

Other exemplary OX40 mediated disorder include infections (viral,bacterial, fungal and parasitic), endotoxic shock associated withinfection, arthritis, rheumatoid arthritis, asthma, bronchitis,influenza, respiratory syncytial virus, pneumonia, chronic obstructivepulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF),cryptogenic fibrosing alveolitis (CFA), idiopathic fibrosinginterstitial pneumonia, emphysema, pelvic inflammatory disease,Alzheimer's Disease, inflammatory bowel disease, Crohn's disease,ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladderdisease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgicaladhesions, stroke, Type I Diabetes, lyme disease, arthritis,meningoencephalitis, autoimmune uveitis, immune mediated inflammatorydisorders of the central and peripheral nervous system such as multiplesclerosis, lupus (such as systemic lupus erythematosus) andGuillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis,fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathicthrombocytopenic purpura, Meniere's disease, pemphigus, primary biliarycirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis,pancreatitis, trauma (surgery), graft-versus-host disease (GVHD),transplant rejection, cardiovascular disease including ischaemicdiseases such as myocardial infarction as well as atherosclerosis,intravascular coagulation, bone resorption, osteoporosis,osteoarthritis, periodontitis, hypochlorhydia and neuromyelitis optica.

Preferred OX40 mediated disorders to be treated with the antibody of theinvention are selected from the group consisting of multiple sclerosis,rheumatoid arthritis, colitis, psoriasis, asthma, COPD, IPF,graft-versus-host-disease (GVHD), atherosclerosis and diabetes. Aparticular preferred OX40 mediated disorders to be treated with theantibody of the invention is graft-versus-host-disease (GVHD).

The present invention also provides an antibody for use in the treatmentof pain, particularly pain associated with inflammation.

In one embodiment, the antibodies of the invention can be used to detectlevels of OX40, or levels of cells which contain OX40 on their membranesurface, which levels can then be linked to certain disease symptoms.Alternatively, the antibodies can be used to inhibit or block OX40function which, in turn, can be linked to the prevention or ameliorationof certain disease symptoms, thereby implicating OX40 as a mediator ofthe disease. This can be achieved by contacting a sample and a controlsample with the OX40 antibody under conditions that allow for theformation of a complex between the antibody and OX40. Any complexesformed between the antibody and OX40 are detected and compared in thesample and the control. In light of the specific binding of theantibodies of the invention for OX40, the antibodies of the inventioncan be used to specifically detect OX40 expression on the surface ofcells e.g. can be used to detect a patient having low expression levelof OX40. The antibodies of the invention can also be used to purify OX40via immunoaffinity purification.

Thus the present invention also provides an in vitro screening method todetect a patient having a low expression level of OX40, comprising thesteps of:

-   -   (a) purifying peripheral blood mononuclear cells (PBMCs) from a        patient blood sample;    -   (b) subjecting the PBMCs to flow cytometric analysis; and    -   (c) determining the number of OX40 positive cells in CD4⁺ and/or        CD8⁺ T cells and comparing this number to control levels.

In a preferred embodiment, a low expression level of OX40 is indicatedby an increase in the expression level of OX40 positive cells whencompared to control levels of up to 10%, more preferably of up to 20%and even more preferably of up to 30%. The approach of determining OX40expression is further described in detail in Kotani A et al., (2001)Blood, 98: 3162-4 and Xiaoyan Z et al., (2005) Clin. Exp. Immunol. 143:110-6.

In another embodiment, the antibodies of the invention can be initiallytested for binding activity associated with therapeutic or diagnosticuse in vitro. For example, compositions of the invention can be testedusing flow cytometric assays.

The present disclosure further provides the use of an antagonistantibody or fragment thereof as a medicament and the use of anantagonist antibody or fragment thereof in the preparation of amedicament for the treatment of an OX40 mediated disorder. In a furtherembodiment the present disclosure provides the antagonist antibody orfragment thereof for use as a medicament. Also provided by the presentdisclosure is the antagonist antibody or fragment thereof for use in amethod for treating an OX40 mediated disorder. OX40 mediated disordersare the ones as described supra. The antagonist antibody of the presentinvention may be particularly useful for treating OX40 mediateddisorders independent of the OX40 costimulatory status of a patient. Ina preferred embodiment, the antagonist antibody or fragment thereof canbe used for treating an OX40 mediated disorder wherein a patientexpresses a low level of OX40.

As previously described, antagonist OX40 antibodies of the invention canbe co-administered with one or other more therapeutic agents, e.g., acytotoxic agent, a radiotoxic agent or an immunosuppressive agent. Theantibody can be linked to the agent (as an immunoconjugate as describedsupra) or can be administered separate from the agent. In the lattercase (separate administration), the antibody can be administered before,after or concurrently with the agent or can be co-administered withother known therapies, e.g., an anti-cancer therapy, e.g., radiation.

For administration of the antibody, the dosage ranges from about 0.0001to 100 mg/kg, and more usually 0.01 to 10 mg/kg, of the host bodyweight. An exemplary treatment regime entails administration once perweek, once every two weeks, once every three weeks, once every fourweeks, once a month, once every 3 months or once every three to 6months. The antibody is usually administered on multiple occasions.Intervals between single dosages can be, for example, weekly, monthly,every three months or yearly. Intervals can also be irregular asindicated by measuring blood levels of antibody to the target antigen inthe patient. In some methods, dosage is adjusted to achieve a plasmaantibody concentration of about 1-1000 μg/ml and in some methods about25-300 μg/ml. Alternatively the antibody can be administered as asustained release formulation, in which case less frequentadministration is required. Dosage and frequency vary depending on thehalf-life of the antibody in the patient. The dosage and frequency ofadministration can vary depending on whether the treatment isprophylactic or therapeutic. In prophylactic applications, a relativelylow dosage is administered at relatively infrequent intervals over along period of time. Some patients continue to receive treatment for therest of their lives. In therapeutic applications, a relatively highdosage at relatively short intervals is sometimes required untilprogression of the disease is reduced or terminated.

Actual dosage levels of the active ingredients, i.e. the antibody in thepharmaceutical compositions of the present invention may be varied so asto obtain an amount of the active ingredient which is effective toachieve the desired therapeutic response for a particular patient,composition, and mode of administration, without being toxic to thepatient. The selected dosage level will depend upon a variety ofpharmacokinetic factors including the activity of the particularcompositions of the present invention employed, the route ofadministration, the time of administration, the rate of excretion of theparticular antibody being employed, the duration of the treatment, otherdrugs, compounds and/or materials used in combination with theparticular compositions employed, the age, sex, weight, condition,general health and prior medical history of the patient being treated,and like factors well known in the medical arts.

A “therapeutically effective amount” of an OX40 antibody of theinvention preferably results in a decrease in severity of diseasesymptoms, an increase in frequency and duration of disease symptom-freeperiods, and/or a prevention of impairment or disability due to thedisease affliction. The ability of a compound for the treatment of anOX40 mediated disorder can be evaluated in an animal model systempredictive of efficacy in human. Alternatively, this property of acomposition can be evaluated by examining the ability of the compound toinhibit cell growth, such inhibition can be measured in vitro by assaysknown to the skilled practitioner. One of ordinary skill in the artwould be able to determine such amounts based on such factors as thesubject's size, the severity of the subject's symptoms, and theparticular composition or route of administration selected.

The antibody or the composition of the present invention can beadministered via one or more routes of administration using one or moreof a variety of methods known in the art. As will be appreciated by theskilled artisan, the route and/or mode of administration will varydepending upon the desired results. Preferred routes of administrationinclude intravenous, intramuscular, intradermal, intraperitoneal,subcutaneous, spinal or other parenteral routes of administration, forexample by injection or infusion. More preferred routes ofadministration are intravenous or subcutaneous. The phrase “parenteraladministration” as used herein means modes of administration other thanenteral and topical administration, usually by injection, and includes,without limitation, intravenous, intramuscular, intraarterial,intrathecal, intracapsular, intraorbital, intracardiac, intradermal,intraperitoneal, transtracheal, subcutaneous, subcuticular,intraarticular, subcapsular, subarachnoid, intraspinal, epidural andintrasternal injection and infusion. Alternatively, an antibody of theinvention can be administered via a non-parenteral route, such as atopical, epidermal or mucosal route of administration, for example,intranasally, orally, vaginally, rectally, sublingually or topically.

Article of Manufacture and Kit

In another embodiment of the disclosure, an article of manufacturecomprising the antagonist antibody or fragment thereof, the compositionor the immunoconjugate of the invention for the treatment of a OX40mediated disorder is provided. The article of manufacture may comprise acontainer and a label or package insert on or associated with thecontainer. Suitable containers include, for example, bottles, vials orsyringes. The containers may be formed from a variety of materials suchas glass or plastic. The container holds a composition that may beeffective for treating the condition and may have a sterile access port(e.g., the container may be an intravenous solution bag or a vial havinga stopper pierceable by a hypodermic injection needle). At least oneactive agent in the composition may be the antagonist antibody describedherein. The label or package insert may indicate that the compositionmay be used for treating the condition of choice, such as cancer. In oneembodiment, the label or package insert may indicate that thecomposition comprising the antagonist antibody may be used to treat anOX40-mediated disorder.

Moreover, the article of manufacture may comprise (a) a first containerwith a composition contained therein, wherein the composition comprisesthe antagonist antibody herein, and (b) a second container with acomposition contained therein, wherein the composition comprises atherapeutic agent other than the antagonist antibody. The article ofmanufacture in this embodiment of the disclosure may further comprise apackage insert indicating that the first and second compositions can beused in combination to treat a OX40 mediated disease or disorder. Suchtherapeutic agent may be any of the adjunct therapies described in thepreceding section (e.g., a thrombolytic agent, an anti-platelet agent, achemotherapeutic agent, an anti-angiogenic agent, an anti-hormonalcompound, a cardioprotectant, and/or a regulator of immune function in amammal, including a cytokine) Alternatively, or additionally, thearticle of manufacture may further comprise a second (or third)container comprising a pharmaceutically acceptable buffer, such asbacteriostatic water for injection (BWFI), phosphate-buffered saline,Ringer's solution and dextrose solution. It may further include othermaterials desirable from a commercial and user standpoint, includingother buffers, diluents, filters, needles, and syringes.

Also within the scope of the present invention are kits comprising theantibody, the compositions or the immunoconjugates of the invention andinstructions for use. The kit can further contain one more additionalreagents, such as an immunosuppressive reagent, a cytotoxic agent or aradiotoxic agent, or one or more additional antagonist antibodies of theinvention (e.g., an antagonist antibody having a complementary activitywhich binds to an epitope in the OX40 antigen distinct from the firstantagonist antibody).

Without further description, it is believed that one of ordinary skillin the art may, using the preceding description and the followingillustrative examples, make and utilize the agents of the presentdisclosure and practice the claimed methods. The following workingexamples are provided to facilitate the practice of the presentdisclosure, and are not to be construed as limiting in any way theremainder of the disclosure.

EXAMPLES Example 1 Generation and Screening of Mouse Anti-Human OX40Antibodies

To produce the recombinant human OX40-Fc protein, a cDNA for the humanTNFRSF4 was purchased from imaGenes (clone number: RZPDB737H0329D;Berlin, Germany). This cDNA was used as a template to PCR-amplify theDNA coding region of the human TNFRSF4 extracellular domain (SEQ ID NO:11). In a separate PCR reaction, the Fc region of a human IgG1 (EUpositions 223-451) was amplified by PCR adding a 5′ GSGGG linker and a3′ SA-6×His linker and restriction sites for cloning. The two resultingproducts were then fused using overlap extension PCR with flankingprimers, adding restriction sites for subsequent cloning into a modifiedmammalian expression vector based on the pcDNA3.1(−) plasmid fromInvitrogen (Invitrogen AG, Basel, Switzerland, Cat. No. V795-20),containing the human CMV promoter with the Ig donor acceptor fragment(first intron) described in U.S. Pat. No. 5,924,939, the OriP sequence(Koons M D et al., (2001) J. Virol. 75(22): 10582-92), the SV40enhancer, and the SV40 polyA fused to the gastrin terminator asdescribed by Kim D, et al., (2003) Biotechnol. Prog. 19(5): 1620-2. Thisrecombinant plasmid allowed for expression of the human TNFRSF4extracellular domain—Fc fusion protein in mammalian cells with secretioninto the cell culture medium driven by the native signal peptide of thehuman TNFRSF4 protein. For recombinant protein production, theaforementioned recombinant vector was transfected intosuspension-adapted HEK 293 cells (ATCC number CRL 1573) using jetPEI™transfection reagent (Polyplus-transfection S.A., Strasbourg, France;distributor: Brunschwig, Basel, Switzerland). The cell culturesupernatant was collected after five days and further purified using aProtein A affinity purification column (HiTrap Protein A sepharosecolumn; GE Healthcare Europe GmbH, Glattbrugg, Switzerland) operated onan ÄKTA FPLC system (GE Healthcare Europe GmbH, Glattbrugg,Switzerland).

To produce the recombinant human OX40-his protein, the extracellularregion of human TNFRSF4 (SEQ ID NO: 11) was amplified by PCR adding a 3′GSG-6×His linker and restriction sites for cloning. The PCR product wassubsequently cloned in the modified pcDNA3.1(−) plasmid described above.This recombinant plasmid allowed for the expression of the humanOX40-his protein in mammalian cells with secretion into the cell culturemedia driven by the native signal peptide of the human TNFRSF4. Forprotein production, the recombinant vector was transfected intosuspension-adapted HEK 293 cells (ATCC number CRL 1573) using jetPEI™transfection reagent (Polyplus-transfection S.A., Strasbourg, France;distributor: Brunschwig, Basel, Switzerland). The cell culturesupernatant was collected five days after transfection and purifiedusing a Ni²⁺-NTA affinity purification column (HiTrap Ni²⁺-NTA sepharosecolumn; GE Healthcare Europe GmbH, Glattbrugg, Switzerland) operated onan ÄKTA FPLC system (GE Healthcare Europe GmbH, Glattbrugg,Switzerland). Recombinant human OX40-Fc and OX40-his proteins were foundto be 95% pure as judged by SDS-PAGE, and further buffered exchangedinto phosphate buffer saline (PBS) prior use.

Recombinant human OX40-Fc protein dissolved in PBS was mixed with anequal volume of Stimune adjuvant (Prionics, Switzerland, ref: 7925000)and an emulsion was prepared. The emulsion was transferred to 0.5 mLinsulin syringes (BD Pharmingen, Allschwil, Switzerland) and BALB/canimals (Harlan, Netherlands) were immunized sub-cutaneously in the backfootpads, the base of the tail and the neck with 50 μg of the emulsifiedprotein. The immunization was repeated two weeks later with the sameamount of antigen and the same route of injection.

The presence of circulating anti-human OX40 antibodies in the immunizedmouse sera was evaluated by direct ELISA using plates coated with therecombinant human OX40-his protein.

A serial dilution (from 1:10° to 1:10⁹) of the different mouse sera wasadded to the plates and the bound antibodies were detected using a goatanti-mouse H+L whole molecule-HRP (Sigma-Aldrich Chemie GmbH, Buchs,Switzerland). A final sub-cutaneous boost with 50 μg of antigen withoutadjuvant was performed in animals displaying the best anti-human OX40IgG serum titer three days before sacrifice.

Animals were euthanized and the inguinal, axillary, brachial, poplitealand sciatic lymph nodes were collected to prepare a single cellsuspension by disturbing the lymph node architecture with two 25Gneedles in a DNAse (Roche Diagnostics (Schweiz) AG, Rotkreuz,Switzerland) and collagenase (Roche Diagnostics (Schweiz) AG, Rotkreuz,Switzerland) solution. Single cell suspensions were fused to a myelomacell line X63AG8.653 (mouse BALB/c myeloma cell line; ATCC accessionnumber: CRL 1580; Kearney J F et al., (1979) J. Immunol. 123(4):1548-1550) at a ratio of 7:1 (fusion partner-to-harvested lymph nodecells) with polyethylene glycol 1500 (Roche Diagnostics (Schweiz) AG,Rotkreuz, Switzerland). The fused cells were plated into 96 well flatbottom plates containing mouse macrophages in DMEM-10 medium (InvitrogenAG, Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS,PAA Laboratories, Pasching, Austria), 2 mM L-glutamine, 100 U/ml(Biochrom AG, Germany) penicillin, 100 μg/ml streptomycin (Biochrom AG,Germany), 10 mM HEPES (Invitrogen AG, Basel, Switzerland), 50 μMβ-mercaptoethanol (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), HAT(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and 1% Growth factor(Hybridokine, Interchim/Uptima, Montlucon, France).

Approximately 800 wells from the fusions were screened by ELISA for thepresence of mouse IgG that recognized human OX40 and blocked the bindingof human OX40L on its receptor. Positive wells were expanded andsubjected to two rounds of subcloning. Cells were collected and theheavy and light chains were cloned and sequenced.

Example 2 Cloning and Sequencing of the VH and VL Chains of theAnti-OX40 Antibodies from Hybridoma Cells

For each positively selected hybridoma, total RNA was prepared,reverse-transcribed into cDNA and VH and VL genes were respectivelyamplified by PCR. These PCR products were ligated into a rescue-vector(pDrive vector; QIAGEN AG, Hombrechtikon, Switzerland; Cat. No. 231124),allowing for the DNA sequencing of individual PCR products and thedetermination of mono- or poly-clonality of the selected hybridomas.This vector allowed for blue/white selection on L B-agar platescontaining IPTG and X-gal (colonies with no insert were blue because ofthe degradation of X-gal by the LacZ α-peptide). Recombinant plasmidsfrom positive (white) bacterial clones were prepared and sequenced usingstandard DNA sequencing primers specific for the vector backbone(M13rev, M13fwd, T7 or SP6). DNA sequences were finally subcloned intoan expression vector for recombinant expression of the antibody ofinterest in mammalian cells.

RNA Isolation

Total RNA was isolated from 2−10×10⁶ cells using the RNeasy Mini Kitfrom QIAGEN (QIAGEN AG, Hombrechtikon, Switzerland; Cat. No. 74106)according to the manufacturer's protocol; samples were quantified usinga NanoDrop ND-1000 spectrophotometer (WITEC AG, Littau, Switzerland).

One Step RT-PCR

The total RNA preparations described above were furtherreverse-transcribed into cDNA, and the VH and VL fragments wereamplified by PCR using two different mixtures of degenerated primers,each one allowing the recovery of all the different subfamilies of mouseimmunoglobulin heavy chain variable fragments and variable heavy chainjunction regions or the recovery of all mouse immunoglobulin light chainkappa variable fragments and variable light chain kappa junctionregions. The primers used for reverse transcription and amplificationwere synthesized by Microsynth (Balgach, Switzerland), and were HPLCpurified (Tables 1-4). Both reverse-transcription and PCR amplificationwere performed simultaneously using the QIAGEN one step RT-PCR kit(QIAGEN AG, Hombrechtikon, Switzerland; Cat. No. 210212). Since thetechnique used specific primers, each mRNA sample was then treated induplicate allowing for the individual reverse-transcription andamplification of either the VH or the VL fragments. 2 μg of total RNAdissolved into RNase-free water to a final volume of 30 μl were mixedwith: 10 μl of a 5× stock solution of QIAGEN OneStep RT-PCR Buffer, 2 μlof a dNTPs mix at a concentration of 10 mM, 3 μl of primer mix at aconcentration of 10 μM and 2 μl of QIAGEN OneStep RT-PCR Enzyme Mix. Thefinal mixture was then placed in a PCR tube, and cycled in aPCR-themocycler (BioRad iCycler version 4.006, Bio-Rad Laboratories AG,Reinach, Switzerland) using the following settings:

30 min at 50° C.

15 min at 95° C.

40 cycles: 30 sec at 94° C.

30 sec at 55° C.

1 min at 72° C.

10 min at 72° C.

Hold at 4° C.

pDrive Cloning

PCR products were run onto 2% agarose gels. Following DNAelectrophoresis, the fragments of interest (˜450 bp) were excised fromthe agarose gels, and further extracted using the Macherey-NagelNucloSpin Extract II kit 250 (Macherey-Nagel, Oensingen, Switzerland;Cat. No. 740609.250). For DNA sequencing, the extracted PCR productswere cloned into the rescue-vector described above (pDrive vector,QIAGEN AG, Hombrechtikon, Switzerland; Cat. No. 231124) and transformedinto the E. coli TOP10 strain (Invitrogen AG, Basel, Switzerland; Cat.No. C404006)

Miniprep Extraction

Positive colonies were cultured overnight at 37° C. (shaking 250 RPM) in1.5 ml of Luria Bertani (LB) medium supplemented with 100 μg/mlampicillin seeded in Macherey-Nagel Square-well Block plates(Macherey-Nagel, Oensingen, Switzerland; Cat. No. 740488.24). The nextday DNA miniprep extractions were performed using the NucleoSpin Multi-8Plasmid kit (Macherey-Nagel, Oensingen, Switzerland; Cat. No. 740620.5).

Sequencing and Sequence Analysis

Samples were sent for DNA sequencing to the DNA sequencing servicecompany Fasteris (Plan-les-Ouates, Switzerland). The standard primers:M13rev, M13fwd, T7, SP6 were used (Table 5). To analyse the DNAsequences, the Clone Manager 9 Professional Edition (Scientific &Educational Software, NC, USA) and the BioEdit Sequence Alignment Editor(Hall, T A (1999) Nucl. Acids. Symp. Ser. 41: 95-98) were used.

Cloning of Expression Vector for Recombinant Chimeric AntibodyExpression

For recombinant expression in mammalian cells, the isolated murine VHand VL fragments were formatted as chimeric immunoglobulins usingassembly-based PCR methods. These chimeric antibodies consist of a heavychain where the murine heavy chain variable domain is fused to the humanIgG1 heavy chain constant domains (γ1, hinge, γ2, and γ3 regions) and alight chain where the murine light chain variable domain is fused to ahuman kappa constant domain (C_(κ)). PCR-assembled murine variable andhuman constant parts were subsequently cloned into a modified mammalianexpression vector based on the modified pcDNA3.1(−) vector fromInvitrogen mentioned in Example 1 with the difference that a humanimmunoglobulin light chain kappa leader peptide was employed to driveprotein secretion. For protein production of the immunoglobulincandidates, equal quantities of heavy and light chain vector DNA wereco-transfected into suspension-adapted HEK-293 (ATCC number: CRL-1573).The cell culture supernatant was collected after five days and purifiedusing a Protein A affinity purification column (HiTrap Protein Asepharose column) operated on an ÄKTA FPLC system (both from GEHealthcare Europe GmbH, Glattbrugg, Switzerland).

TABLE 1 primer Mix VH-back GTGATC GCC ATG GCG TCG ACC GAK GTR MAG CTT CAG GAG TC GTGATC GCC ATG GCG TCG ACC GAG GTB CAG CTB CAG CAG TC GTGATC GCC ATG GCG TCG ACC CAG GTG CAG CTG AAG SAR TC GTGATC GCC ATG GCG TCG ACC GAG GTC CAR CTG CAA CAR TC GTGATC GCC ATG GCG TCG ACC CAG GTY CAG CTB CAG CAR TC GTGATC GCC ATG GCG TCG ACC CAG GTY CAR CTG CAG CAR TC GTGATC GCC ATG GCG TCG ACC CAG GTC CAC GTG AAG CAR TC GTGATC GCC ATG GCG TCG ACC GAG GTG AAS STG GTG GAR TC GTGATC GCC ATG GCG TCG ACC GAV GTG AWG STG GTG GAG TC GTGATC GCC ATG GCG TCG ACC GAG GTG CAG STG GTG GAR TC GTGATC GCC ATG GCG TCG ACC GAK GTG CAM CTG GTG GAR TC GTGATC GCC ATG GCG TCG ACC GAG GTG AAG CTG ATG GAR TC GTGATC GCC ATG GCG TCG ACC GAG GTG CAR CTT GTT GAR TC GTGATC GCC ATG GCG TCG ACC GAR GTR AAG CTT CTC GAR TC GTGATC GCC ATG GCG TCG ACC GAA GTG AAR STT GAG GAR TC GTGATC GCC ATG GCG TCG ACC CAG GTT ACT CTR AAA SAR TC GTGATC GCC ATG GCG TCG ACC CAG GTC CAA CTV CAG CAR CC GTGATC GCC ATG GCG TCG ACC GAT GTG AAC TTG GAA SARTC GTGATC GCC ATG GCG TCG ACC GAG GTG AAG  GTC ATC GAR TC

TABLE 2 primer Mix VH-forwardCCTCCACCACTCGAGCC CGA GGA AAC GGT GAC CGT GGTCCTCCACCACTCGAGCC CGA GGA GAC TGT GAG AGT GGTCCTCCACCACTCGAGCC CGC AGA GAC AGT GAC CAG AGTCCTCCACCACTCGAGCC CGA GGA GAC GGT GAC TGA GGT

TABLE 3 primer Mix VL-back GGCGGTGGC GCT AGC GAY ATC CAG CTG ACT CAG CCGGCGGTGGC GCT AGC CAA ATT GTT CTC ACC CAG TCGGCGGTGGCGCT AGC GAY ATT GTG MTM ACT CAG TCGGCGGTGGC GCT AGC GAY ATT GTG YTR ACA CAG TCGGCGGTGGC GCT AGC GAY ATT GTR ATG ACM CAG TCGGCGGTGGC GCT AGC GAY ATT MAG ATR AMC CAG TCGGCGGTGGC GCT AGC GAY ATT CAG ATG AYD CAG TCGGCGGTGGCGCT AGC GAY ATY CAG ATG ACA CAG ACGGCGGTGGC GCT AGC GAY ATT GTT CTC AWC CAG TCGGCGGTGGCGCT AGC GAY ATT GWG CTS ACC CAA TCGGCGGTGGC GCT AGC GAY ATT STR ATG ACC CAR TCGGCGGTGGC GCT AGC GAY RTT KTG ATG ACC CAR ACGGCGGTGGCGCT AGC GAY ATT GTG ATG ACB CAG KCGGCGGTGGC GCT AGC GAY ATT GTG ATA ACY CAG GAGGCGGTGGC GCT AGC GAY ATT GTG ATG ACC CAG WTGGCGGTGGC GCT AGC GAY ATT GTG ATG ACA CAA CCGGCGGTGGCGCT AGC GAY ATT TTG CTG ACT CAG TCGGCGGTGGC GCT AGC GAA ACA ACT GTG ACC CAG TCGGCGGTGGCGCT AGC GAA AAT GTK CTS ACC CAG TCGGCGGTGGCGCT AGC CAG GCT GTT GTG ACT CAG GAA TC

TABLE 4 primer Mix VL-forwardATGCTGAC GC GGC CGC ACG TTT KAT TTC CAG CTT GGATGCTGAC GC GGC CGC ACG TTT TAT TTC CAA CTT TGATGCTGAC GC GGC CGC ACG TTT CAG CTC CAG CTT GGATGCTGAC GC GGC CGC ACC TAG GAC AGT CAG TTT GG

TABLE 5 sequencing primers M13-Fwd GTAAAACGACGGCCAGT M13-RevAACAGCTATGACCATG T7 TAATACGACTCACTATAGG SP6 GATTTAGGTGACACTATAG

Example 3 Biological Characterization of Anti-Human OX40 AntibodiesOX40-Specific Antibody Detection ELISA:

Antibody titers, specificity and production by hybridomas andrecombinant antibody candidates were determined by a direct ELISA.Briefly, 96 well-microtiter plates (Costar USA, distributor VWR AG,Nyon, Switzerland) were coated with 100 μl of recombinant human OX40-hisat 2 μg/ml in PBS (see Example 1 for the generation of the OX40-hisprotein). Plates were incubated overnight at 4° C. and were then blockedwith PBS 2% BSA (Bovine Serum Albumine, PAA Laboratories, Pasching,Austria) at room temperature (RT) for one hour. The blocking solutionwas removed and the hybridoma supernatants or purified antibodies wereadded. The plates were incubated at RT for 30 minutes, then washed ninetimes with PBS 0.01% Tween-20 (Sigma-Aldrich Chemie GmbH, Buchs,Switzerland) and a Horseradish Peroxidase (HRP) labelled-Goat anti-mouseH+L-detection antibody (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland)was added at a dilution of 1:1000. To detect recombinant chimericantibodies (see Example 2) that possess a human Fc, a HRP-labeled rabbitanti human IgG antibody (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland)at a dilution of 1:1000 was used as the detection antibody. Plates wereincubated for 30 minutes at room temperature (RT), washed nine timeswith PBS 0.01% Tween-20 and the TMB substrate (Bio-rad Laboratories AG,Reinach, Switzerland) was added to the plates and the reaction stoppedafter six minutes by adding H₂SO₄. Absorbance was then read at 450 nm bya microplate reader (Biotek, USA; distributor: WITTEC AG, Littau,Switzerland). FIG. 1A shows that the chimeric 1D4 antibody and thechimeric 2F8 antibody recognize the OX40-his coated protein.

OX40L Blocking ELISA:

The recombinant human OX40 ligand protein (OX40L) was generated asfollowed: the cDNA for human TNFSF4 (clone name: 10H46203) was purchasedfrom imaGenes (Berlin, Germany) and the extracellular portion (aminoacids 51-183) of human TNFSF4 ligand (numbering according to the UniprotQ6FGS4 sequence) was amplified with flanking restriction sites. Theresulting PCR product encompassing an ASA linker and a 8-His tagsequence at its 5′ end was subsequently cloned into a modified versionof the pREP4 vector from Invitrogen (Invitrogen AG, Basel, Switzerland)carrying a CMV promoter, a Bovine Growth Hormone poly-adenylation, andthe murine VJ2C leader peptide to drive the secretion of the recombinantprotein. For recombinant protein production, the reconbinant vector wastransfected into suspension-adapted HEK 293 cells (ATCC number CRL 1573)using jetPEI™ transfection reagent (Polyplus-transfection S.A.,Strasbourg, France; distributor: Brunschwig, Basel, Switzerland). Cellculture supernatant was collected after five days and purified using aProtein A affinity purification column (HiTrap Protein A sepharosecolumn; GE Healthcare Europe GmbH, Glattbrugg, Switzerland) operated onan ÄKTA FPLC system (GE Healthcare Europe GmbH, Glattbrugg,Switzerland).

In order to determine if the generated anti-OX40 antibodies can blockthe binding of OX40L to the OX40 receptor, a blocking ELISA wasdeveloped. Ninety-six well-microtiter plates (Costar, USA; distributorVWR AG, Nyon, Switzerland) were coated with 100 μl of recombinant humanOX40-Fc (see Example 1) at 2 μg/ml in PBS. Plates were incubatedovernight at 4° C. and were then blocked with PBS 2% BSA at RT for onehour. The blocking solution was removed and the hybridoma supernatantsor purified antibodies were added to the plate. Five minutes later, 50μl of biotinylated-recombinant human OX40L at 0.04 mg/ml was added toeach well. Plates were incubated at RT for 60 minutes, then washed ninetimes with PBS 0.01% Tween-20 and HRP-streptavidin (Sigma-Aldrich ChemieGmbH, Buchs, Switzerland) was added at a dilution of 1:2000. Plates wereincubated for 30 minutes at RT, washed 9 times with PBS 0.01% Tween-20and the TMB substrate (Bio-rad Laboratories AG, Reinach, Switzerland)was added to the plates and the reaction stopped after 6 minutes byadding H₂SO₄. Absorbance was then read at 450 nm by a microplate reader(Biotek, USA; distributor: WITTEC AG, Littau, Switzerland). FIG. 1Bshows that the chimeric 1D4 antibody is able to block the interactionbetween OX40 and OX40L in a dose dependent manner, whereas the chimeric2F8 antibody is not able to block the interaction between OX40 andOX40L.

Human Mixed Lymphocyte Reaction (MLR)

Blood from two different donors was collected in three 10 mL S-Monovettewith citrate as an anti-coagulant (Sarstedt, Nümbrecht, Germany). Cellsfrom donor No 1 were used as effector cells whereas cells from donor No2 were used as target cells. PBMCs (peripheral blood mononuclear cells)from the 2 donors were purified using 50 mL Blood-Sep-Filter Tubes(distributor: Brunschwig, Basel, Switzerland) following themanufacturer's instructions. Cells were washed 2 times with Roswell ParkMemorial Institute (RPMI, PAA Laboratories, Pasching, Austria) mediumwithout FBS. The target cells were incubated with 50 μg/ml of mitomycinC (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) for 30 minutes at 37°C. Cells were then washed 3 times with RPMI without FBS and resuspendedat 1×10⁶ cell/mL in RPMI, 10% FBS (PAA Laboratories, Pasching, Austria),2 mM L-glutamine (Lonza, Leuven, Belgium), 100 U/ml penicillin, 100μg/ml streptomycin (Biochrom AG, Berlin, Germany). In 96 well U bottommicro-plates (TPP, Trasadingen, Switzerland), 50′000 target cells and80′000 effector cells were distributed in a final volume of 100 μA toeach well. One hundred IA of antibody dilutions was added to the wells.Plates were incubated for 7 days at 37° C. in 5% CO₂ incubator. Sevendays after the start of the MLR, cells were pulsed with 0.5 μCi of ³Hthymidine (Perkin Elmer). 18 hours after pulsing, cells were harvestedand incorporated radioactivity was quantified on a Wallac beta counter.FIG. 2 shows that the chimeric 1D4 antibody is able to block the MLR ina dose dependent manner to a higher degree than the positive control.

Example 4 Binding of Anti-Human OX40 Antibodies on Human and OtherAnimal Specie Activated Peripheral Blood Mononuclear Cells (PBMC) byFlow Cytometry Human Cells

Filters containing human leukocytes were collected from the BloodCollection Center from La Chaux-de-Fonds, Switzerland (Centre deTransfusion Sanguine et Laboratoire de Sérologie, rue Sophie-Mairet 29,CH-2300). Cells were removed from the filters by backflushing with 60 mLof PBS containing 10 U/mL of liquemin (Drossapharm AG, Lucern,Switzerland). PBMCs were then purified with 50 mL Blood-Sep-Filter Tubes(distributor: Brunschwig, Basel, Switzerland) following manufacturer'sinstructions. Cells were washed 3 times with Roswell Park MemorialInstitute (RPMI, PAA Laboratories, Pasching, Austria) medium with FBS(PAA Laboratories, Pasching, Austria). Cells were resuspended at 3×10⁶cells/ml in RPMI, 10% FBS (PAA Laboratories, Pasching, Austria), 2 mMUltraglutamine (Lonza, Leuven, Belgium), 100 U/ml penicillin, 100 μg/mlstreptomycin (Biochrom AG, Berlin, Germany), 10 μg/ml ofPhytohemagglutinin (PHA; Sigma-Aldrich Chemie GmbH, Buchs,Switzerland)+100 U/mL of rHu IL-2 (Proleukin, Novartis, Basel,Switzerland) in a 24 well plate (TPP, Trasadingen, Switzerland).Forty-eight hours later, cells were collected and analyzed by flowcytometry as described below.

HPB-ALL cells (T acute lymphoid leukemia cell line, from DeutscheSammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig,Germany) were cultured in RPMI, 10% FBS. 2×10⁵ cells were distributed ina 96 well V bottom plate (TPP, Trasadingen, Switzerland), andcentrifuged for three minutes at 1300 rpm; supernatants were discarded,cells were collected and analyzed by flow cytometry as described below.

PBMCs and HPB-ALL cells prepared as described above were resuspended in50 μA of FACS buffer (PBS, 2% FBS, 10% Versene (Invitrogen, USA) with 5μg/mL of chimeric 1D4 antibody or 5 μg/mL or an appropriate isotypecontrol or 20 μA of a PE-labelled commercial anti-human OX40 antibody(clone L106, BD Biosciences, Allschwil, Switzerland). Cells wereincubated for 30 minutes on ice, washed two times and resuspended in 50μA of FACS buffer. An anti-human IgG-Phycoerithrin-PE (BD Biosciences,Allschwil, Switzerland) diluted 1/200 was used to detect the chimeric1D4 antibody and the isotype control antibody. Cells were incubated for15 minutes on ice, washed once, resuspended in 400 μl of FACS buffer andanalyzed on the FACS instrument (Cyan, Beckman Coulter InternationalS.A., Nyon, Switzerland).

Cynomolgus Monkey Primary Cells

Whole blood from Cynomolgus monkeys (obtained from Professor EricRouiller, Laboratory of Neurophysiology, University of Fribourg,Fribourg, Switzerland), was collected in citrate tubes (BD Biosciences,Allschwil, Switzerland). Two mL of PBS was mixed with 3 mL of blood andthe mixture was layered on the top of 10 ml of a 85:15 Ficoll:PBSmixture (GE Healthcare Europe GmbH, Glattbrugg, Switzerland). Sampleswere centrifuged for 20 minutes at room temperature without break. ThePBMC layer was collected and washed three times with PBS. Cells wereresuspended at 3×10⁶ cells/mL in Dulbecco's Modified Eagle Medium (DMEM,PAA Laboratories, Pasching, Austria), 10% FBS (PAA Laboratories,Pasching, Austria), Non-essential amino acids (PAA Laboratories,Pasching, Austria) 1 mM Sodium Pyruvate (PAA Laboratories, Pasching,Austria), 2 mM Ultraglutamine (Lonza, Belgium), 100 U/ml penicillin(Biochrom AG, Germany), 100 μg/ml streptomycin (Biochrom AG, Germany).One mL of the cell suspension was distributed in a 24 well plate (TPP,Trasadingen, Switzerland) and 10 ug/ml of PHA (PHA/M, Sigma-AldrichChemie GmbH, Buchs, Switzerland) 100 U/mL of rHu IL-2 (Proleukin,Novartis, Basel, Switzerland) were added. Cells were incubated for 50hours at 37° C. in 5% CO₂ incubator. Activated PBMC were collected andresuspended in PBS/2.5% FBS (FACS buffer). Fifty thousand cells in 50 μlof FACS buffer were distributed in a 96 well V bottom plate andbiotinylated anti-human OX40-chimeric 1D4 antibody or biotinylatedisotype control antibody or biotinylated commercial anti-human OX40raised in sheep (BD Biosciences, Allschwil, Switzerland) were added tothe wells at 25 μg/ml. Samples were incubated for 20 minutes on ice andthen cells were washed two times with cold FACS buffer and thenincubated with Streptavidin-PE (BD Biosciences, Allschwil, Switzerland)at a 1:20 dilution for 15 minutes on ice. Cells were washed once withFACS buffer and then resuspended in 300 μA of FACS buffer. PropidiumIodide at a volume of 2 μl (PI; Sigma-Aldrich Chemie GmbH, Buchs,Switzerland) was added in each sample to exclude dead cells. Cells wereanalyzed by flow cytometry (Cyan, Beckman Coulter International S.A.,Nyon, Switzerland).

FIGS. 3A and 3B shows that the chimeric 1D4 antibody is able torecognize OX40 expressed on the surface of human and cynomologus monkeyactivated lymphocytes, respectively, thus provides for cross-reactivityproperties highly desired for drug development.

Example 5 Kinetic Binding Affinity Constants of the Chimeric 1D4Antibody for Human OX40 Receptor Extracellular Domain by Surface PlasmonResonance (SPR)

Kinetic binding affinity constants (KD) were measured on protein-Acaptured antibody using recombinant histidine tagged human OX40 receptorextracellular domain as described in Example 1 as analyte. Measurementswere conducted on a B IAcore 2000 (GE Healthcare-BIAcore, Uppsala,Sweden) at room temperature, and analyzed with the BiaEvaluationsoftware (BIAcore; v4.1).

A CM5 research grade sensor chip (GE Healthcare Europe GmbH, Glattbrugg,Switzerland; BR-1000-14) was activated by injecting 35 μl of a 1:1N-hydroxysulfosuccinimide(NHS)/1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride (EDC)solution (v/v; 5 μl/min flow-rate; on flow paths 1 and 2). Protein-A(ref. P7837; Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) was dilutedto a final concentration of 50 μg/ml in acetate buffer pH 4.5 (GE,BR-1003-50; one pH unit below pI) and subsequently immobilized on thepreviously activated CM5 sensor chip by injecting 35 μl on both flowpath 1 and 2 (5 μl/min); this corresponded to approximately 1500response units (RUs). The protein-A-CM5 sensor chip was then deactivatedby injecting 35 μl of ethanolamine solution (5 μl/min). Finally, twoinjections of 10 μA of glycine solution (GE, ref. BR-1003-54; 10 mM; pH1.5) were performed to release non-crosslinked protein-A molecules.

Before affinity measurements, a mass transfer limitation test wasperformed by injecting a fixed concentration of analyte onto a fixedquantity of protein-A captured antibody at different flow-rates (5, 15,30, 50, 75 μl/min for 2 min). Analysis of the on-rate slopes atdifferent flow-rates indicated mass transfer.

For affinity measurements, the chimeric 1D4 antibody stored in 1×PBSbuffer was diluted to a final concentration of 15 nM in HBS-EP buffer(GE, ref. BR-1001-88; 0.01 M Hepes, 0.15 M NaCl, EDTA 3 mM, 0.005%Surfactant P20, pH 7.4). 10 μl of this diluted stock were subsequentlyinjected on the flow-path 2 of the protein-A CM5 chip (30 μl/min) toreach 200-250 RUs. Following this capture step, the recombinanthistidine tagged human OX40 receptor extracellular domain was injectedat different concentrations (50 nM to 0.4 μM) on the flow-path 1 and 2(flow-path 1 being used as reference) at a 30 μl/min flow rate. Aftereach binding event, surface was regenerated with glycine buffer pH 1.5injected for 1 min (10 μl/min).

Measurements (sensorgram: fc2-fc1) were best fitted with a 2:1 bivalentanalyte model with mass transfer. To account for the experimentalvariations in protein-A captured antibody at the beginning of eachmeasurement, the Rmax value was set to local in all fits. Dissociationtimes were of at least 300-600 seconds. Measurements were performed induplicate and included zero-concentration samples for referencing. TheChi2 value represents the sum of squared differences between theexperimental data and reference data at each point; while the plots ofresiduals indicate the difference between the experimental and referencedata for each point in the fit. Both Chi2 and residual values were usedto evaluate the quality of a fit between the experimental data andindividual binding models.

Measurements were performed in duplicates with the captured chimeric 1D4anti-human OX40 antibody immobilized onto the protein-A sensor chip andthe recombinant histidine tagged human OX40 receptor extracellulardomain as analyte. KD value was between 91 and 116 nM with Chi2 values<1.25.

Example 6 Humanization of Mouse Monoclonal Antibody 1D4

Humanizing the anti-human OX40 mouse antibody 1D4 including selection ofhuman acceptor frameworks, back mutations, and mutations thatsubstantially retain and/or improve the binding properties of humanCDR-grafted acceptor frameworks is described herein.

Design of the Reshaped Variable Regions

Homology matching was used to choose human acceptor frameworks to graft1D4 CDRs. Databases e.g. a database of germline variable genes from theimmunoglobulin loci of human and mouse (the IMGT database (theinternational ImMunoGeneTics information System®; Lefranc M P et al.,(1999) Nucleic Acids Res. 27(1): 209-12; Ruiz M et al., (2000) NucleicAcids Res. 28(1): 219-21; Lefranc M P (2001) Nucleic Acids Res. 29(1):207-9; Lefranc M P (2003) Nucleic Acids Res. 31(1): 307-10; Lefranc M Pet al., (2005) Dev. Comp. Immunol. 29(3): 185-203; Kaas Q et al., (2007)Briefings in Functional Genomics & Proteomics, 6(4): 253-64) or theVBASE2 (Retter I et al., (2005) Nucleic Acids Res. 33, Database issueD671-D674) or the Kabat database (Johnson G et al., (2000) Nucleic AcidsRes. 28: 214-218)) or publications (e.g., Kabat E A et al., supra) maybe used to identify the human subfamilies to which the murine heavy andlight chain V regions belong and determine the best-fit human germlineframework to use as the acceptor molecule. Selection of heavy and lightchain variable sequences (VH and VL) within these subfamilies to be usedas acceptor may be based upon sequence homology and/or a match ofstructure of the CDR1 and CDR2 regions to help preserve the appropriaterelative presentation of the six CDRs after grafting.

For example, use of the IMGT database indicates good homology betweenthe 1D4 heavy chain variable domain framework and the members of thehuman heavy chain variable domain subfamily 2. Highest homologies andidentities of both CDRs and framework sequences were observed forgermline sequences: IGHV 2-70*10 (SEQ ID NO: 19), IGHV2-70*01 (SEQ IDNO: 20), IGHV2-70*13 (SEQ ID NO: 21), IGHV2-5*09 (SEQ ID NO: 22), andIGHV2-70*11 (SEQ ID NO: 23), all of which having sequence identity above73% for the whole sequence up to CDR3. IGHV 2-70*10, IGHV2-70*01, andIGHV2-70*13 have a sequence identity of 74%; while IGHV2-5*09, andIGHV2-70*11 have a sequence identity of 73.5% and 73%, respectively.

Using the same approach, 1D4 light chain variable domain sequence showedgood homology to the members of the human light chain variable domainkappa subfamily 3. Highest homologies and identities of both CDRs andframework sequences were observed for germline sequences: IGKV3-11*01(SEQ ID NO: 24) (65.3% identity), IGKV1-39*01 (SEQ ID NO: 25) (64.9%identity), IGKV1D-39*01 (SEQ ID NO: 26) (64.9% identity), IGKV3-11*02(SEQ ID NO: 27) (64.2% identity), and IGKV3-20*01 (SEQ ID NO: 28) (62.5%identity).

As starting point to the humanization process, human IGHV 2-70*10 (SEQID NO: 19), and IGKV3-11*01 (SEQ ID NO: 24) variable domains wereselected as acceptors to the 1D4 CDRs. IGHV 2-70*10 was selected overother human heavy chain variable domains for its superior homology with1D4 in its framework one region.

A first humanized antibody of human gamma one isotype was prepared (seebelow). The antibody encompassed a human-mouse hybrid heavy chainvariable domain and a human-mouse hybrid light chain variable domain.The hybrid heavy chain variable domain was based on the human heavychain variable domain IGHV 2-70*10 wherein germline CDR1 and 2 whererespectively replaced for 1D4 heavy chain CDR1 and 2. Best matching JHsegment sequence to the human acceptor framework was identified from theIMGT searches mentioned above. The resulting human-mouse hybrid heavychain variable sequence having human IGHV 2-70*10 framework regions, 1D4mouse CDRs, and best matching JH to human acceptor is refereed herein asheavy chain variable domain VH1 with SEQ ID NO: 29. Similarly, thehuman-mouse hybrid light chain variable domain used for this firsthumanized antibody candidate had human IGKV3-11*01 framework regions,1D4 mouse CDRs, and best matching JK to human acceptor, and is refereedherein as light chain variable domain VL1 with SEQ ID NO: 30. The firsthumanized antibody encompassing VH1 and VL1 is abbreviated hereinVH1/VL1 antibody.

Production of the First Humanized Antibody Prototype

Coding DNA sequences (cDNAs) for VH1 and VL1 were synthesized in a scFvformat by GENEART AG (Regensburg, Germany) thereby allowing for a singleDNA sequence to encompass both variable domains (SEQ ID NO: 31).Individual variable domain cDNAs were retrieved from this scFv constructby PCR, and further assembled upstream of their respective constantdomain cDNA sequence(s) using PCR assembly techniques. Finally, thecomplete heavy and light chain cDNAs were ligated in independent vectorsthat are based on a modified pcDNA3.1 vector (Invitrogen, CA, USA)carrying the CMV promoter and a Bovine Growth Hormone poly-adenylationsignal. The light chain specific vector allowed expression of humankappa isotype light chains by ligation of the light chain variabledomain cDNA of interest in front of the kappa light chain constantdomain cDNA using BamHI and BsiWI restriction enzyme sites; while theheavy chain specific vector was engineered to allow ligation of theheavy chain variable domain cDNA of interest in front of the cDNAsequence encoding the human IGHG1 CH1, IGHG1 hinge region, IGHG1 CH2,and IGHG1 CH3 constant domains using BamHI and SalI restriction enzymesites. In both heavy and light chain expression vectors, secretion wasdriven by the mouse VJ2C leader peptide containing the BamHI site. TheBsiWI restriction enzyme site is located in the kappa constant domain;whereas the SalI restriction enzyme site is found in the IGHG1 CH1domain.

The VH1/VL1 antibody was transiently produced by co-transfecting equalquantities of heavy and light chains vectors into suspension-adaptedHEK293-EBNA1 cells (ATCC® catalogue number: CRL-10852) usingpolyethylenimine (PEI, Sigma, Buchs, Switzerland). Typically, 100 ml ofcells in suspension at a density of 0.8-1.2 million cells per ml istransfected with a DNA-PEI mixture containing 50 μg of expression vectorencoding the heavy chain and 50 μg of expression vector encoding thelight chain. When recombinant expression vectors encoding antibody genesare introduced into the host cells, antibodies are produced by furtherculturing the cells for a period of 4 to 5 days to allow for secretioninto the culture medium (EX-CELL 293, HEK293-serum-free medium; Sigma,Buchs, Switzerland), supplemented with 0.1% pluronic acid, 4 mMglutamine, and 0.25 μg/ml geneticin).

The VH1/VL1 antibody was purified from cell-free supernatant usingrecombinant protein-A streamline media (GE Healthcare Europe GmbH,Glattbrugg, Switzerland), and buffered exchanged into phosphate buffersaline prior to assays. Binding to human OX40 was measured by SPR asdescribed in Example 5.

Back Mutations of Grafted Human Frameworks

Since straight grafting of CDRs from 1D4 mouse antibody led to acandidate having no binding to human OX40 (Table 6 and FIG. 4),mutagenesis wherein human residues are substituted for mouse residueswas initiated. This process is called back-mutation and is the mostunpredictable procedure in the humanization of monoclonal antibodies. Itnecessitates the identification and the selection of critical frameworkresidues from the mouse antibody that need to be retained in order topreserve affinity while at the same time minimizing potentialimmunogenicity in the humanized antibody. Table 7, Table 8, and FIG. 5show residues (Kabat numbering) that differ between mouse and humanantibody frameworks. Residues which may affect the conformations of CDRsor inter-variable domain packing are of particular interest since thesemay have the highest impact on antibody affinity.

To identify residues that may impact the most CDR conformation and/orinter-variable domain packing, a 3D model for the VH1-VL1 pair ofvariable domains was calculated using the structure homology-modellingserver SWISS-MODEL (Arnold K et al., (2006) Bioinformatics, 22(2):195-201; http://swissmodel.expasy.org) set in automated mode. Modelanalysis allowed the selection of a subset of positions based on theirputative influence on CDR regions and/or heavy chain-light chainvariable domain packing. This subset of positions consisted of variableheavy chain positions: 23, 35b, 48, 50, 60, and 62 as well as variablelight chain positions: 1, 33, 34, 46, 47, 54, 56, and 71 (Kabatnumbering). In addition to these back mutations, light chain positionY31 found in the VH1/VL1 antibody was deleted in some candidates.

Further humanized candidates based on various combinations of heavy andlight chain substitutions were prepared in the context of the VH1/VL1antibody sequence using standard mutagenesis and methods describedabove. Humanized antibody candidates were assayed for their bindingaffinity by SPR as described in Example 5.

Production yields and binding properties of some of the humanizedantibodies based on these single or combination of substitutions areshown in Table 6. Out of the 28 antibodies shown, nine candidates didnot show any binding to human OX40, and another group of nine had weakto poor binding. VL9 based humanized antibodies showed the mostconsistently to weakly bind human OX40 by SPR. Only two antibodies,VH6/VL9 and VH7/VL9 showed good binding to human OX40. Both humanizedantibodies had back mutations at variable heavy chain positions: 23,35b, 50, 60, and 62 and variable light chain positions: 33, 34, 46, 47and 71 (Kabat numbering). In addition to these back mutations, bothVH6/VL9 and VH7/VL9 benefited from the removal of light chain position31. Surprisingly VH7/VL9 had improved affinity for human OX40 over 1D4chimeric antibody and the VH6/VL9 variant. The binding affinities ofthese humanized antibodies are summarized in Table 9.

Thermostability of Selected Humanized Anti-OX40 Antibodies byDifferential Scanning Calorimetry

The thermal stabilities of the humanized antibodies were measured usingdifferential scanning calorimetry (DSC). Monoclonal antibodies meltingprofiles are characteristic of their isotypes (Garber E & Demarest S J(2007) Biochem. Biophys. Res. Commun. 355: 751-7), however the mid-pointmelting temperature of the FAB fragment can be easily identified even inthe context of a full-length IgG. Such mid-point melting of FAB portionwas used to monitor monoclonal stability of the humanized candidates.

calorimetric measurements were carried out on a VP-DSC differentialscanning microcalorimeter (MicroCal, Northampton, UK). The cell volumewas 0.128 ml, the heating rate was 200° C./h, and the excess pressurewas kept at 65 p.s.i. All antibodies were used at a concentration of 1mg/ml in PBS (pH 7.4). The molar heat capacity of antibody was estimatedby comparison with duplicate samples containing identical buffer fromwhich the antibody had been omitted. The partial molar heat capacitiesand melting curves were analyzed using standard procedures. Thermogramswere baseline corrected and concentration normalized before beingfurther analyzed using a Non-Two State model in the software Originv7.0.

Humanized variant VH6/VL9 FAB fragment displayed a single transition at76.3° C. with a shape and amplitude consistent with a cooperativeunfolding which is generally observed for a compactly folded FABfragments indicating that the engineering process was successful atretaining FAB stability. Overall the humanized variant showed a goodthermal stability.

TABLE 6 humanized anti human OX40 antibodies Humanized antibodyTransient Binding variant SEQ ID Mutations expression to human (IGHG1)NOs VH/VL (mg/l) OX40 VH1/VL1 32, 39 N.A./N.A. 40 No VH1/VL2 32, 40N.A./L33M 21 No VH1/VL3 32, 41 N.A./F71Y 17 No VH2/VL1 33, 39 T23S/N.A.13 No VH2/VL2 33, 40 T23S/L33M 17 No VH2/VL3 33, 41 T23S/F71Y 14 NoVH3/VL1 34, 39 R50H/N.A. 23 No VH3/VL2 34, 40 R50H/L33M 22 No VH3/VL334, 41 R50H/F71Y 18 No VH4/VL4 35, 42 T23S-R50H/ 15 Poor L33M-F71YVH4/VL9 35, 47 T23S-R50H/ 3 Weak Y31deletion-L33M- A34H-L46P-L47W- F71YVH5/VL4 36, 42 T23S-R50H- 15 Poor S60N-S62A/ L33M-F71Y VH5/VL5 36, 43T23S-R50H- 2 Poor S60N-S62A/ L33M-L46P- L47W-F71Y VH5/VL6 36, 44T23S-R50H- 2 Poor S60N-S62A/ E1Q-L33M-L46P- L47W-F71Y VH5/VL9 36, 47T23S-R50H-S60N- 6 Weak S62A/Y31deletion- L33M-A34H- L46P-L47W-F71YVH6/VL5 37, 43 T23S-S35bG- 0 N.D. R50H-S60N-S62A/ L33M-L46P- L47W-F71YVH6/VL6 37, 44 T23S-S35bG-R50H- 0.5 N.D. S60N-S62A/ E1Q-L33M-L46P-L47W-F71Y VH6/VL7 37, 45 T23S-S35bG- 14 N.D. R50H-S60N-S62A/Y31deletion- L33M-F71Y VH6/VL8 37, 46 T23S-S35bG-R50H- 7 N.D. S60N-S62A/Y31deletion- L33M-A34H-F71Y VH6/VL9 37, 47 T23S-S35bG-R50H- 3.5 GoodS60N-S62A/ Y31deletion-L33M- A34H-L46P-L47W- F71Y VH6/VL10 37, 48T23S-S35bG-R50H- 0.5 N.D. S60N-S62A/ Y31deletion-L33M- R54L-T56S-F71YVH6/VL11 37, 49 T23S-S35bG-R50H- 5.5 N.D. S60N-S62A/ Y31deletion-L33M-A34H-R54L-T56S- F71Y VH7/VL5 38, 43 T23S-S35bG-I48L- 1 N.D.R50H-S60N-S62A/ L33M-L46P-L47W- F71Y VH7/VL6 38, 44 T23S-S35bG-I48L- 1N.D. R50H-S60N-S62A/ E1Q-L33M-L46P- L47W-F71Y VH7/VL7 38, 45T23S-S35bG-I48L- 1.5 Weak R50H-S60N-S62A/ Y31deletion-L33M- F71Y VH7/VL838, 46 T23S-S35bG-I48L- 10 Weak R50H-S60N-S62A/ Y31deletion-L33M-A34H-F71Y VH7/VL9 38, 47 T23S-S35bG-I48L- 3 Good R50H-S60N-S62A/Y31deletion-L33M- A34H-L46P-L47W- F71Y VH7/VL11 38, 49 T23S-S35bG-I48L-11.5 Weak/ R50H-S60N-S62A/ Good Y31deletion-L33M- A34H-R54L-T56S- F71Y

TABLE 7 comparison of 1D4 and human acceptor heavy chain variable IGHV2-70*10 frameworks Kabat CDR grafted position 1D4 IGHV 2-70*10 10 G A 11I L 12 L V 13 Q K 15 S T 19 S T 23 S T  35b G S 41 S P 44 G A 48 L I 50H R 60 N S 62 A S 65 S T 66 G R 79 F V 81 K T 82 I M  82a A T  82b S N 82c Y M 84 T P 85 T V

TABLE 8 comparison of 1D4 and human acceptor light chain variable IGKV3-11*01 frameworks Kabat CDR grafted position 1D4 IGKV 3-11*01 1 Q E 10I T 13 A L 18 K R 19 V A 21 M L 22 T S 33 M L 34 H A 42 S Q 43 S A 45 KR 46 P L 47 W L 54 L R 56 S T 58 V I 70 S D 71 Y F 72 S T 76 N S 77 R S78 V L 80 A P 83 A F 85 T V

TABLE 9 binding characteristics of selected humanized and chimeric antiOX40 antibodies. SEQ ID Humanized variants NOs k_(on) (1/Ms) k_(off)(1/s) K_(D) (nM) 1D4 chimera 50, 51  3.4 × 10⁴ 3.08 × 10⁻³ 91 VH6/VL937, 47 3.54 × 10⁴ 3.56 × 10⁻³ 101 VH7/VL9 38, 47 4.45 × 10⁴ 3.12 × 10⁻³70

Example 7 Epitope Characterization of Humanized Anti-OX40 Antibodies

To characterize the epitope of the humanized anti-OX40 antibodies, theVH6/VL9 antibody was mapped to a define domain of the human OX40extracellular region using various human-rat OX40 chimeric proteins.

Preparation of Human-Rat OX40 Chimeric Proteins and ELISA

Rat and human-rat OX40 proteins were formatted as Fc fusions proteinsaccording to the method described in Example 1. For the ELISA, OX40proteins were coated at 2 μg/mL, in PBS, overnight at 4° C. on highbinding 96-well plates (Coastar). The plates were blocked with PBS 2%Bovine Serum Albumin (BSA) before incubation with the VH6/VL9 antibodyor isotype control antibody. The plates were then washed and incubatedwith goat-anti human Ig F(ab′)2 fragment specific-HRP (JacksonImmunoResearch Europe Ltd, Newmarket, UK). After washing, the plateswere incubated with TMB substrate (Bio-Rad Laboratories AG, Reinach,Switzerland) to reveal antibody binding. The reaction was stopped byadding 2M H₂SO₄ and the optical density was read at 450 nM (OD 450 nM)on a Synergy HT2 spectrophotometer (Biotek, USA; distributor: WITTEC AG,Littau, Switzerland).

Results

Regardless of its origin, the OX40 extracellular region has been dividedinto four structural modules referred to as domain 1, 2, 3 and 4(Compaan D M & Hymowitz S G (2006) Structure, 14(8): 1321-30). ChimericOX40 proteins corresponding to the extracellular region of human OX40(amino acids 29-214 of human TNFRSF4, numbering according to the UniprotP43489 sequence) were constructed by exchanging one or more of the fourdomains between human and rat sequences. For example, the chimeric RHRROX40 protein corresponds to the rat OX40 extracellular region whereinthe second domain has been replaced by the corresponding human domainsequence.

A binding ELISA was performed to test the reactivity of the VH6/VL9antibody on human OX40 extracellular region (abbreviated HHHH with SEQID NO: 11), rat OX40 extracellular region (abbreviated RRRR with SEQ IDNO: 52), and on four human-rat chimeric proteins: RHRR (SEQ ID NO: 53),HRRR (SEQ ID NO: 54), HHRR (SEQ ID NO: 55), and RRHH (SEQ ID NO: 56).The result of this ELISA is shown in FIG. 7. As a prerequisite to thisepitope mapping experiment, the VH6/VL9 antibody was shown to bind thehuman OX40 protein but not the rat OX40 protein, indicating that therewas no cross-reactivity to rat OX40. It was found that the VH6/VL9antibody bound RHRR and HHRR but not HRRR or RRHH, indicating thatVH6/VL9 epitope maps within the second domain of human OX40extracellular region.

Example 8 VH6/VL9 Antibody Blocks Human Mix Lymphocyte Reaction byKilling and Blocking Mechanisms

The potency of VH6/VL9 antibody to suppress in vitro immune reactionswas tested in a one-way allogeneic mixed lymphocyte reaction (MLR). TheMLR is an in vitro model of alloreactive T cell activation andproliferation (O'Flaherty E et al., (2000) Immunology, 100(3): 289-99;DuPont B & Hansen J A (1976) Adv. Immunol. 23: 107-202). When peripheralblood mononuclear cells (PBMCs) from two unrelated donors are mixed, Tcells get activated through recognition of allogeneic majorhistocompatibility (MHC) molecules. This activation results inproliferation of T lymphocytes. The MLR reaction has been widely used todemonstrate the effect of T-cell targeting immunosuppressive drugs(Bromelow K V et al., (2001) J. Immunol. Methods, 247(1-2): 1-8).Immunosuppressive drugs, such as cyclosporine work mainly throughinhibiting T cell activation. Besides testing the blocking effect by theVH6/VL9 antibody, the contribution of cytotoxic mechanisms such asantibody dependent cellular cytotoxicity (ADCC) on the inhibition of MLRwas also investigated. Three different antibody formats of the VH6/VL9antibody were tested in this assay: an IGHG1 format (referred herein asVH6/VL9), a non fucosylated IGHG1 (IgG1) format (referred herein as nonfucosylated VH6/VL9), and an IGHG4 (IgG4) format (referred herein asVH6/VL9 IGHG4 S228P). IGHG1 (IgG1) antibodies are known to be competentfor cytotoxicity mechanism such as ADCC. Non fucosylated IGHG1antibodies are known to exhibit enhanced ADCC activity due to a higheraffinity for the FcγRIIIa expressed on cytotoxic cells such as naturalkiller cells (NK cells) (Mizushima T et al., (2011) Genes Cells, 16(11):1071-80). In contrast, IGHG4 (IgG4) antibodies are known to have no suchFc-mediated cytotoxicity mechanisms such as ADCC.

Formatting of the VH6/VL9 Antibody

IGHG4 immunoglobulin formatting having substitution S228P was achievedby replacing the cDNA sequence encoding the IGHG1 CH1, IGHG1 hingeregion, IGHG1 CH2, and IGHG1 CH3 constant domains for a cDNA sequenceencoding the IGHG4 CH1, IGHG4 hinge region having S228P substitution,IGHG4 CH2 and IGHG4 CH3 constant domains in the heavy chain specificvector described in Example 6. Substitution S228P was introduced in ahuman IGHG4 heavy chain cDNA template by standard PCR mutagenesistechniques. The resulting heavy chain has SEQ ID NO: 57. Production ofthe non-fucosylated VH6/VL9 IGHG1 antibody followed the protocoldescribed in Example 14 of the WO2010/095031 publication.

Mixed Lymphocyte Reaction

Blood from two different human donors was collected in three 10 mLS-Monovette with citrate as an anti-coagulant (Sarstedt, Nümbrecht,Germany). Peripheral blood mononuclear cells (PBMCs) from the two humandonors were purified using 50ML Blood-Sep-Filter Tubes (distributor:Brunschwig, Basel, Switzerland) following the Manufacturer'sinstructions. Cells were washed two times with Roswell Park MemorialInstitute (RPMI, PAA Laboratories, Pasching, Austria) medium withoutFBS. Stimulator cells from the two donors were prepared by incubationwith 50 μg/ml of mitomycin C (Sigma-Aldrich Chemie GmbH, Buchs,Switzerland) for 30 minutes at 37° C. Cells were then washed three timeswith RPMI without FBS and resuspended at 1×10⁶ cell/mL in RPMI, 10% FBS(PAA Laboratories, Pasching, Austria), 2 mM L-glutamine (Lonza, Leuven,Belgium), 100 U/ml penicillin and 100 μg/ml streptomycin (Biochrom AG,Berlin, Germany). Responder cells were resuspended in RPMI, 10% FBS,L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in 96 well Ubottom micro-plates (TPP, Trasadingen, Switzerland). 50′000 stimulatorcells and 80′000 responder cells were distributed in a final volume of100 μl to each well. 100 μl of antibody dilutions (or medium only) wasadded to the wells. Plates were incubated for 7 days at 37° C. in 5% CO₂incubator. The cells were pulsed with 0.5 μCi of ³H thymidine (PerkinElmer, Basel Switzerland) during the last 18 hours. Cells were harvestedon a filtermat filter (Perkin Elmer) and incorporated radioactivity wasquantified on a Wallac beta counter (Perkin Elmer).

Results

The results shown on FIG. 8 demonstrate that the VH6/VL9 antibody isable to efficiently inhibit MLR for two different individuals(responders) with EC₅₀ values around 100 ng/mL. The results also show adifferent response depending on the antibody format used and adifference in the contribution of blocking and cytotoxic mechanisms isobserved in the MLR from different individuals.

The reactivity of T cells from responder 1 (FIG. 8A) was efficientlyinhibited by the IGHG1 and IGHG4 formats indicating that cytotoxicmechanisms are not critical for responder 1. In contrast, the IGHG4format was only poorly able to block the MLR from responder 2 (FIG. 8B)at high concentration and lost very rapidly its effect at lowerconcentrations, whereas the IGHG1 format could achieve more than 60% ofinhibition, implying that, for responder 2, killing mechanisms areaccounting for most of the inhibitory effect.

This difference in mode of action likely arises from the fact thatactivation, proliferation and survival of T cells in a MLR reaction isvariably reliant on OX40 costimulatory signals between individuals,depending on the extent of allergenic reactivity and possibly othercostimulatory signals. For individuals poorly dependant on OX40-derivedcostimulatory signals, elimination of activated T cells by ADCCmechanism is the main mechanism of action of the VH6/VL9.

Surprisingly, the non fucosylated IGHG1 format displayed a very potentability to inhibit MLR for both responders. This observation highlightsthe fact that even if a blocking mechanism may be sufficient to achieveinhibition of MLR, addition or enhancement of killing mechanismsimproves the inhibitory effect of anti-OX40 antibodies. Such enhancementis particularly useful when in treating OX40 mediated disordersregardless of the OX40 costimulatory status of patients, e.g whenpatients have low OX40 expression levels.

Example 9 VH6/VL9 Antibody Blocks Xenogeneic Graft-Versus-Host-Disease

Xenogeneic graft versus host (GVH) reaction is a model for theallogeneic graft versus host disease (GVHD) observed after bone marrowtransplant in human patients. The GVH reaction is an acute immuneresponse mediated by grafted immune cells which attack the hostenvironment as a consequence of an allogeneic or xenogeneic MHCrecognition (Murphy W J et al., (1996) Semin. Immunol. 8(4): 233-41). Tlymphocytes are the main effector cells of GVH reactions. Theimmunosuppressive potency of the VH6/VL9 antibody was tested in axenogeneic GVHD model based on the reconstitution of SCID mice withhuman PBMCs. In this model, human PBMCs and primarily the T lymphocyteslaunch a strong response against the mouse host cells. The reactionleads notably to severe skin and intestinal inflammation accompanied byweight loss. The most relevant readout of this model is the survival ofthe animals.

Method

Animals (SCID mice) were sub-lethally irradiated before beingreconstituted with 30 million human PBMCs intraperitoneally. The micewere also depleted for mouse NK cells by twice weekly injections withthe TMbetal antibody. The treatment with VH6/VL9 antibody, Enbrel® orvehicle was given i.v. weekly for five consecutive doses and started twodays before the PBMC injection. Animals were treated either with vehicle(PBS) or the VH6/VL9 antibody at 10 mg/kg or 1 mg/kg, or Enbrel® (afusion protein of the human soluble TNF receptor 2 fused to the Fccomponent of human IgG1, Amgen-Pfizer) at 8 mg/kg. The animals werechecked and scored three times weekly for GVHD symptoms including weightloss, diarrhoea, fur aspect and general behaviour. Animals wereethically sacrificed if symptoms were considered too severe.

Results

FIG. 9 shows that the VH6/VL9 antibody very potently suppressed the GVHDreaction even at the lower, 1 mg/kg dose. Surprisingly, the VH6/VL9antibody demonstrated improved efficacy over Enbrel®, which is arecognized therapy for GVHD in human (Xhaard A et al., (2011) Bull.Cancer, 98(8): 889-99; Simpson D (2001) Expert Opin. Pharmacother. 2(7):1109-17). The median survival time of animals treated with the VH6/VL9antibody at 1 or 10 mg/kg was four-fold longer compared to the vehicletreated group (Table 10) and two-fold longer compared to Enbrel®. Inaddition this result highlights that the VH6/VL9 antibody possesses noagonistic activity, since an agonistic anti-OX40 antibody has beenreported to worsen GVHD in allogeneic mouse GVHD models (Valzasina B etal., (2005) Blood, 105(7): 2845-51; Blazar B R et al., (2003) Blood,101(9): 3741-8), an event that was not observed in the present study.

TABLE 10 Median survival time (in days) of the indicated treatmentgroups 1D4 1D4 Treatment Vehicle Enbrel ® (1 mg/kg) (10 mg/kg) Survivalmedian 11.5 20.5 42 47.5 (days) Vehicle: only PBS. 1D4: GBR 830-1D4antibody; Enbrel ® was the clinical product.

1-73. (canceled)
 74. A method for treating an OX40-mediated disorder ina subject in need thereof, the method comprising administering to thesubject a therapeutically effective amount of an antagonistic antibodyor fragment thereof that binds to human OX40 comprising a heavy chainCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chainCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chainCDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/orcomprising a light chain CDR1 comprising the amino acid sequence of SEQID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQID NO: 5 and a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO:
 6. 75. The method of claim 74, wherein the antibody orfragment thereof is a murine antibody, chimeric antibody or a humanizedantibody.
 76. The method of claim 74, wherein the antibody or fragmentthereof is a Humanized antibody.
 77. The method of claim 74, wherein theantibody or fragment thereof comprises a heavy chain variable regionsequence comprising the amino acid sequence of SEQ ID NO:
 7. 78. Themethod of claim 74, wherein the antibody or fragment thereof comprises anon-CDR region of a heavy chain variable region sequence which is atleast 80% identical to the non-CDR region of the heavy chain variableregion sequence of SEQ ID NO:
 7. 79. The method of claim 74, wherein theheavy chain sequence comprises a non-CDR region which is at least 80%identical to the non-CDR region of the heavy chain variable regionsequence of the heavy chain sequence selected from the group consistingof SEQ ID NOS: 35, 36, 37 or
 38. 80. The method of claim 79, wherein theantibody or fragment thereof comprises a heavy chain sequence comprisingthe amino acid sequence selected from the group consisting of SEQ IDNOS: 35, 36, 37 and
 38. 81. The method of claim 74, wherein the antibodyor fragment thereof comprises a heavy chain variable region sequencecomprising the amino acid sequence selected from the group consisting ofSEQ ID NOS: 58, 59, 79 and
 80. 82. The method of claim 74, wherein theantibody or fragment thereof comprises a non-CDR region of a heavy chainvariable region sequence which is at least 80% identical to the non-CDRregion of the heavy chain variable region sequence selected from thegroup consisting of SEQ ID NOS: 58, 59, 79 and
 80. 83. The method ofclaim 74, wherein the antibody or fragment thereof comprises a heavychain variable framework region that is the product of a human geneselected from the group consisting of IGHV2-70*10 (SEQ ID NO: 19),IGHV2-70*01 (SEQ ID NO: 20), IGHV2-70*13 (SEQ ID NO: 21), IGHV2-5*09(SEQ ID NO: 22), and IGHV2-70*11 (SEQ ID NO: 23).
 84. The method ofclaim 74, wherein the antibody or fragment thereof comprises a heavychain variable framework region that is the product of human geneIGHV2-70*10 (SEQ ID NO: 19) and wherein the heavy chain variableframework region comprises at least one amino acid modification, whereinthe amino acid modification comprises an amino acid substitution fromthe corresponding heavy chain variable framework region of thecorresponding murine antibody of SEQ ID NO:
 7. 85. The method of claim74, wherein the antibody or fragment thereof comprises a heavy chainsequence comprising the amino acid sequence of SEQ ID NO: 32 and whereinthe heavy chain variable framework region comprises at least one aminoacid modification, wherein the amino acid modification comprises anamino acid substitution from the corresponding heavy chain variableframework region of the corresponding murine antibody of SEQ ID NO: 7.86. The method of claim 84, wherein the amino acid substitution is at anamino acid position selected from the group consisting of 23, 35b, 48,50, 60 and 62, wherein the amino acid position of each group member isindicated according to the Kabat numbering.
 87. The method of claim 85,wherein the amino acid substitution is at an amino acid positionselected from the group consisting of 23, 35b, 48, 50, 60, and 62,wherein the amino acid position of each group member is indicatedaccording to the Kabat numbering.
 88. The method of claim 84, whereinthe amino acid substitution is selected from the group consisting of23S, 35bG, 48L, 50H, 60N, and 62A, wherein the amino acid position ofeach group member is indicated according to the Kabat numbering.
 89. Themethod of claim 85, wherein the amino acid substitution is selected fromthe group consisting of 23S, 35bG, 48L, 50H, 60N, and 62A, wherein theamino acid position of each group member is indicated according to theKabat numbering.
 90. The method of claim 74, wherein the antibody orfragment thereof comprises a light chain variable region sequencecomprising the amino acid sequence of SEQ ID NO:
 8. 91. The method ofclaim 74, wherein the antibody or fragment thereof comprises a non-CDRregion of a light chain variable region sequence which is at least 80%identical to the non-CDR region of the light chain variable regionsequence of SEQ ID NO:
 8. 92. The method of claim 74, wherein the lightchain sequence comprises a non-CDR region which is at least 80%identical to the non-CDR region of the light chain variable regionsequence of the light chain sequence selected from the group consistingof SEQ ID NOS: 45, 46, 47 and
 49. 93. The method of claim 92, whereinthe antibody or fragment thereof comprises a light chain sequencecomprising the amino acid sequence selected from the group consisting ofSEQ ID NOS: 45, 46, 47 and
 49. 94. The method of claim 74, wherein theantibody or fragment thereof comprises a light chain variable regionsequence comprising the amino acid sequence selected from the groupconsisting of SEQ ID NOS: 60, 86, 87 and
 89. 95. The method of claim 74,wherein the antibody or fragment thereof comprises a non-CDR region of alight chain variable region sequence which is at least 80% identical tothe non-CDR region of the light chain variable region sequence selectedfrom the group consisting of SEQ ID NOS: 60, 86, 87 and
 89. 96. Themethod of claim 74, wherein the antibody or fragment thereof comprises alight chain variable framework region that is the product of a humangene selected from the group consisting of IGKV3-11*01 (SEQ ID NO: 24),IGKV1-39*01 (SEQ ID NO: 25), IGKV1D-39*01 (SEQ ID NO: 26), IGKV3-11*02(SEQ ID NO: 27) and IGKV3-20*01 (SEQ ID NO: 28).
 97. The method of claim74, wherein the antibody or fragment thereof comprises a light chainvariable framework region that is the product of human gene IGKV3-11*01(SEQ ID NO: 24) and wherein the light chain variable framework regioncomprises at least one amino acid modification, wherein the amino acidmodification comprises an amino acid substitution or deletion from thecorresponding framework region of the light chain variable region of thecorresponding murine antibody of SEQ ID NO:
 8. 98. The method of claim74, wherein the antibody or fragment thereof comprises a light chainsequence comprising the amino acid sequence of SEQ ID NO: 39 and whereinthe light chain variable framework region comprises at least one aminoacid modification, wherein the amino acid modification comprises anamino acid substitution or deletion from the corresponding light chainvariable framework region of the corresponding murine antibody of SEQ IDNO:
 8. 99. The method of claim 97, wherein the amino acid substitutionis at an amino acid position selected from the group consisting of 1,33, 34, 46, 47, 54, 56, and 71, wherein the amino acid position of eachgroup member is indicated according to the Kabat numbering.
 100. Themethod of claim 98, wherein the amino acid substitution is at an aminoacid position selected from the group consisting of 1, 33, 34, 46, 47,54, 56, and 71, wherein the amino acid position of each group member isindicated according to the Kabat numbering.
 101. The method of claim 97,wherein the amino acid substitution is selected from the groupconsisting of 1Q, 33M, 34H, 46P, 47W, 54L, 56S, and 71Y, wherein theamino acid position of each group member is indicated according to theKabat numbering.
 102. The method of claim 98, wherein the amino acidsubstitution is selected from the group consisting of 1Q, 33M, 34H, 46P,47W, 54L, 56S, and 71Y, wherein the amino acid position of each groupmember is indicated according to the Kabat numbering.
 103. The method ofclaim 97, wherein the amino acid deletion is at amino acid position 31,wherein the amino acid position is indicated according to the Kabatnumbering.
 104. The method of claim 98, wherein the amino acid deletionis at amino acid position 31, wherein the amino acid position isindicated according to the Kabat numbering.
 105. The method of claim 74,wherein the antibody or fragment thereof comprises: (a) a heavy chainsequence comprising the amino acid sequence of SEQ ID NO: 37 or SEQ IDNO: 38; and (b) a light chain sequence comprising the amino acidsequence of SEQ ID NO:
 47. 106. The method of claim 74, wherein theantibody or fragment thereof comprises: (a) a heavy chain variableregion sequence comprising the amino acid sequence of SEQ ID NO: 58 orSEQ ID NO: 59; and (b) a light chain variable region sequence comprisingthe amino acid sequence of SEQ ID NO:
 60. 107. The method of claim 74,wherein the antibody or fragment thereof comprises a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chainCDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/orcomprises a light chain CDR1 comprising the amino acid sequence of SEQID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQID NO: 5 and a light chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 6, wherein at least one of the heavy chain CDRs and/or atleast one of the light chain CDRs comprises no more than three aminoacid modifications, wherein the amino acid modification is an amino acidsubstitution, insertion and/or deletion.
 108. The method of claim 74,further comprising heavy and/or light constant regions.
 109. The methodof claim 108, wherein the human heavy constant region is selected fromthe group of human immunoglobulins consisting of IGHG1, non fucosylatedIGHG1 and IGHG4.
 110. The method of claim 74, wherein the antibody is amonovalent antibody.
 111. The method of claim 74, wherein the antibodyis a full length antibody.
 112. The method of claim 74, wherein theantibody is an antibody fragment selected from the group consisting ofFab, Fab′, Fab′-SH, Fd, Fv, dAb, F(ab′)2, scFv, bispecific single chainFv dimers, diabodies, triabodies and scFv genetically fused to the sameor a different antibody.
 113. The method of claim 74, wherein theantibody comprises a variant Fc region which comprises at least oneamino acid modification relative to the Fc region of the parentantibody, whereas the antibody comprising the variant Fc region exhibitsaltered effector function compared to the parent antibody.
 114. Themethod of claim 74, wherein the antibody or fragment thereof binds tohuman OX40 with an affinity (KD) of 110 nM or less.
 115. The method ofclaim 74, wherein the antibody or fragment thereof retains at least 75%of the OX40 binding affinity (K_(D)) of the corresponding chimericantibody.
 116. The method of claim 74, wherein the antibody or fragmentthereof has equivalent or higher OX40 binding affinity (K_(D)) whencompared to the corresponding chimeric antibody.
 117. The method ofclaim 74, wherein the antibody has a FAB fragment thermostabilitytemperature greater than 75° C.
 118. The method of claim 74, wherein theantibody or fragment thereof that binds to human OX40 binds to the sameepitope as the antibody comprising a heavy chain CDR1 comprising theamino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising theamino acid sequence of SEQ ID NO: 2, a heavy chain CDR3 comprising theamino acid sequence of SEQ ID NO: 3; and/or comprising a light chainCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chainCDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a lightchain CDR3 comprising the amino acid sequence of SEQ ID NO:
 6. 119. Themethod of claim 74, the method comprising administering to the subject acomposition comprising a therapeutically effective amount of anantagonistic antibody or fragment thereof that binds to human OX40comprising a heavy chain CDR1 comprising the amino acid sequence of SEQID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQID NO: 2, a heavy chain CDR3 comprising the amino acid sequence of SEQID NO: 3; and/or comprising a light chain CDR1 comprising the amino acidsequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acidsequence of SEQ ID NO: 5 and a light chain CDR3 comprising the aminoacid sequence of SEQ ID NO: 6, and a pharmaceutically acceptablecarrier.
 120. The method of claim 74, the method comprisingadministering to the subject an immunoconjugate comprising atherapeutically effective amount of an antagonistic antibody or fragmentthereof that binds to human OX40 comprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising alight chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, alight chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 anda light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6linked to a therapeutic agent.
 121. The method of claim 74, the methodcomprising administering to the subject an immunoconjugate comprising atherapeutically effective amount of an antagonistic antibody or fragmentthereof that binds to human OX40 comprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR3comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising alight chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, alight chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 anda light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6linked to a therapeutic agent and a pharmaceutically acceptable carrier.122. The method of claim 119, wherein the composition further comprisesanother pharmaceutically active agent.
 123. The method of claim 120,wherein the immunoconjugate further comprises a pharmaceuticallyacceptable carrier and another pharmaceutically active agent.
 124. Themethod of claim 74, wherein the OX40 mediated disorder is selected fromthe group consisting of infections (viral, bacterial, fungal andparasitic), endotoxic shock associated with infection, arthritis,rheumatoid arthritis, COPD, pelvic inflammatory disease, Alzheimer'sDisease, inflammatory bowel disease, Crohn's disease, ulcerativecolitis, Peyronie's Disease, coeliac disease, gallbladder disease,Pilonidal disease, peritonitis, psoriasis, vasculitis, surgicaladhesions, stroke, Type I Diabetes, lyme disease, arthritis,meningoencephalitis, autoimmune uveitis, immune mediated inflammatorydisorders of the central and peripheral nervous system such as multiplesclerosis, lupus (such as systemic lupus erythematosus) andGuillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis,fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathicthrombocytopenic purpura, Meniere's disease, pemphigus, primary biliarycirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, otherautoimmune disorders, pancreatitis, trauma (surgery), cardiovasculardisease including ischaemic diseases such as myocardial infarction aswell as atherosclerosis, intravascular coagulation, bone resorption,osteoporosis, osteoarthritis, periodontitis, hypochlorhydia andneuromyelitis optica.
 125. The method of claim 74, wherein the OX40mediated disorder is selected from the group consisting of infections(viral, bacterial, fungal and parasitic), endotoxic shock associatedwith infection, arthritis, rheumatoid arthritis, bronchitis, influenza,respiratory syncytial virus, pneumonia, COPD, idiopathic pulmonaryfibrosis (IPF), cryptogenic fibrosing alveolitis (CFA), idiopathicfibrosing interstitial pneumonia, emphysema, pelvic inflammatorydisease, Alzheimer's Disease, inflammatory bowel disease, Crohn'sdisease, ulcerative colitis, Peyronie's Disease, coehac disease,gallbladder disease, Pilonidal disease, peritonitis, psoriasis,vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme disease,arthritis, meningoencephalitis, autoimmune uveitis, immune mediatedinflammatory disorders of the central and peripheral nervous system suchas multiple sclerosis, lupus (such as systemic lupus erythematosus) andGuillain-Barr syndrome, Atopic dermatitis, autoimmune hepatitis,fibrosing alveolitis, Grave's disease, IgA nephropathy, idiopathicthrombocytopenic purpura, Meniere's disease, pemphigus, primary biliarycirrhosis, sarcoidosis, scleroderma, Wegener's granulomatosis, otherautoimmune disorders, pancreatitis, trauma (surgery), cardiovasculardisease including ischaemic diseases such as myocardial infarction aswell as atherosclerosis, intravascular coagulation, bone resorption,osteoporosis, osteoarthritis, periodontitis, hypochlorhydia andneuromyelitis optica.
 126. The method of claim 74, wherein the subjecthas a low expression level of OX40.
 127. The method of claim 74, whereinthe antibody has enhanced cytotoxicity as compared to the antibodyhaving human heavy chain constant region IGHG1.
 128. An article ofmanufacture comprising the antibody or fragment thereof of the method ofclaim 74 for the treatment of an OX40 mediated disorder, wherein theOX40 mediated disorder is selected from the group consisting of:multiple sclerosis, rheumatoid arthritis, colitis, psoriasis, COPD, IPF,atherosclerosis and diabetes.
 129. A kit comprising the antibody orfragment thereof of the method of claim 74 for the treatment of an OX40mediated disorder, wherein the OX40 mediated disorder is selected fromthe group consisting of: multiple sclerosis, rheumatoid arthritis,colitis, psoriasis, COPD, IPF, atherosclerosis and diabetes.